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RESUMO 
 
O câncer de cabeça e pescoço é o quarto em incidência e o quinto em mortalidade na lista das 
neoplasias mais frequentes no mundo. Para o ano de 2014, são estimados pouco mais de 15 
mil novos casos de câncer oral e de orofaringe no Brasil. 
Assim como outros tumores, o câncer oral e de orofaringe é uma doença multifatorial 
decorrente de fatores ambientais e genéticos, envolvendo diversas alterações em mecanismos 
moleculares importantes para a homeostase celular. 
A investigação de marcadores moleculares envolvidos nesses mecanismos tem sido o objeto 
de estudo de muitos grupos de pesquisa, uma vez que, apesar do crescente avanço em técnicas 
terapêuticas, a sobrevida desses pacientes pouco tem aumentado nas ultimas décadas. 
É sabido que a progressão do tumor depende de que suas células adquirem algumas 
competências, como por exemplo, evasão da apoptose mediada pelo sistema imunológico, 
disfunção no controle da proliferação celular, proliferação celular facilitada pela ativação 
angiogênica, adaptações celulares como resposta à hipóxia tumoral, ativação do mecanismo 
de sobrevivência celular e modificações epigenéticas dependentes de hipóxia. 
Considerando sua atuação nesses mecanismos, o presente trabalho teve o objetivo de avaliar o 
potencial das proteínas FAS, FASL, FGFR4, LEPR, HIF1-a, NDRG1 e JMJD1a e os 
polimorfismos Gly388Arg no gene FGFR4 e Gln223Arg no gene LEPR, como possíveis 
marcadores moleculares para as características clinicopatológicas e o prognóstico de pacientes 
com o carcinoma epidermóide oral e de orofaringe. 
Nossos resultados mostraram a expressão HIF1-alpha relacionada com a recidiva local da 
doença e sobrevida livre de doença local nos pacientes submetidos à radioterapia pós-
operatória, sendo também relacionada com a microdensidade vascular tumoral.  
Adicionalmente, a expressão NDRG1 foi diferente quando comparadas as amostras de tecido 
tumoral e margem cirurgica não tumoral, também mostrando relação com a sobrevida da 
doença. 
Com relação ao FGFR4, a expressão e o polimorfismo Gly388Arg mostraram relação com a 
ocorrência do óbito e com a sobrevida da doença. Contudo, apenas a expressão FGFR4 
mostrou relação com com a metástase linfonodal e a ocorrência de recidiva. O perfil FGFR4 
proposto mostrou relação com a sobrevida da doença. 
Sobre o sistema FAS/FASL, ambas expressões mostraram relação com a ocorrência do óbito 
e o perfil FAS/FASL proposto foi significantemente relacionado com a sobrevida da doença. 
O polimorfismo Gln223Arg no gene LEPR mostrou relação com a sobrevida livre de doença 
e da doença específica, enquanto que a expressão LEPR mostrou relação com a metástase 
linfonodal. 
Á respeito da proteína JMJD1A, tanto a expressão nuclear quanto a citoplasmática mostraram 
relação com a metastase linfonodal. Contudo, apenas a expressão nuclear JMJD1A mostrou 
relação com a ocorrência de recidiva e com a sobrevida da doença. 
Em conclusão, nossos resultados sugerem que as proteínas e polimorfismos avaliados podem 
ser utilizados como marcadores moleculares para auxiliar na predição prognóstica de 
pacientes com carcinoma epidermóide oral e de orofaringe. 
 
Palavras chaves: Câncer cabeça e pescoço; prognóstico; apoptose; proliferação celular; 
hipóxia; angiogênese. 
ABSTRACT 
 
Head and neck cancer is the fourth in incidence and the fifth in mortality among the most 
frequent malignancies worldwide. For 2014, there has been estimated over 15 thousand new 
oral and oropharynx cancers in Brasil. 
Similar to other tumors, oral and oropharynx cancer is a multifactorial disease, caused by 
multiple environmental and genetic factors, involving alterations in molecular pathways and 
cellular homeostasis. 
The investigation of molecular markers involved in this process has been the object of my 
studies, especially because in spite of great advances in the molecular aspects of cancer, little 
progress has been made in the clinical outcome during the last decades. 
It is known that tumor progression depends on cellular aquisition of competences, such as 
apoptosis evasion, cell proliferation disregulation, angiogenic activation, cellular adaptation to 
hipoxia, cell survival mechanism activation and hypoxia dependent epigenetic changes. 
Therefore, the present work had the purpose to evaluate the potential of proteins FAS, FASL, 
FGFR4, LEPR, HIF1-a, NDRG1 and JMJD1a, as well as polymorphisms FGFR4 Gly388Arg 
and LEPR Gln223Arg, as putative molecular markers for clinicopathological tumor features 
or oral and oropharynx squamous cell carcinoma. 
Our results show that HIF1-1 expression was associated with local disease relapse and local 
disease-free survival in patients who undertook pos-operative radiotherapy and were also 
related to tumor vascular microdensity. 
In addition, NDRG1 expression was different in tumor tissue and non tumoral margins, but 
also showing an association with disease survival. 
FGFR4 polymorphism and expression showed a relation with death and disease survival. 
However, FGFR4 expression alone showed an association with lymph node metastasis and 
relapse. FGFR4 profile showed a relation with disease survival. 
FAS/FASL expression showed a correlation with death and its proposed profise was related 
with disease survival. 
LEPR Gln223Arg polymorphism was realted with disease free survival and disease specific 
survival, whereas LEPR expression was realted with lymph node metastasis. 
JMJD1A nuclear and cytoplasmic expression were related with lymph node metastasis. 
However, only nuclear expression was related with relapse and disease survival. 
In conclusion, our results suggest that proteins ans polymorphisms can be used as molecular 
markers to help predict prognosis in oral and oropharynx squamous cell carcinoma. 
 
Keywords: Head and neck cancer; prognosis; apoptosis; cell proliferation; hypoxia; 
angiogenesis. 
  
LISTA DE SIGLAS E ABREVIATURAS 
 
A - Adenina 
ARD1 - Acetyltransferase Arrest-defective-1 
Arg - Arginina 
ARNT - Aryl Hydrocarbon Receptor Nuclear Translocator 
bHLH-PAS - basic Helix-Loop-Helix-Per-ARNT-Sim 
CD178 - Nomenclatura alternativa para FASL 
CD95 - Nomenclatura alternativa para FAS 
C-TAD - C-terminal 
DNA - Deoxyribonucleic Acid (em português, Ácido desoxirribonucleico) 
FADD - FAS-associated Death Domain 
FAS - Fas Cell Surface Death Receptor 
FASL - Fas Cell Surface Death Receptor Ligand 
Fe - Ferro 
FGF - Fibroblast growth factor 
FGFR - Fibroblast Growth Factor Receptor 
G - Guanina 
Gln - Glutamina 
Gln223Arg - Substituição de uma glutamina por uma arginina no aminoácido 223 
Gly - Glicina 
Gly388Arg - Substituição de uma glicina por uma arginina no aminoácido 388 
H3K9me1 - Lisinas 9 das Histonas H3 monometilada 
H3K9me2 - Lisinas 9 das Histonas H3 dimetilada 
HIF - Hypoxia-inducible factor 
HIF1-a - Hypoxia-inducible factor 1-alpha 
HPV - Human Papillomavirus 
HRE - Hypoxia Response Element 
JAK - Janus Kinase 
JMJD1A - JMJ C-domain-containing histone demethylase 1A 
LEPR - Leptin Receptor 
Lys - Lisina 
MMP-9 - Matriz Metalloproteinase-9 
NDRG1 - N-myc downstream regulated gene 1 
N-TAD - N-terminal 
ODD - Oxygen-regulated Degradation 
p53 - Protein 53 (em português, proteína 53) 
PHD - Prolyl Hydroxylation 
pVHL - protein von Hippel-Lindau 
SIRT1 - Sirtuin 1 
SNP - Single Nucleotide Polymorphism 
STAT - Signal Transducer and Activator of Transcription 
TNM - Tumor, Linfonodo e Metástase 
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1. INTRODUÇÃO 
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O carcinoma epidermóide de cabeça e pescoço é uma causa significativa de morbidade 
e mortalidade em todo o mundo, com aproximadamente 780.000 casos e 391.000 mortes por 
ano, sua taxa de mortalidade atinge 50% dos casos em 5 anos [1,2]. 
A doença diagnosticada em seu estágio inicial tem expectativa de sobrevida livre da 
doença variando entre 60 a 90%. Nos casos restantes, quando a doença é detectada em estágio 
avançado, cerca de 50% dos casos têm tumores potencialmente ressecáveis com chance de 
sobrevida variando em 40-50%. Nos casos avançados e não ressecáveis, o prognóstico é pior, 
com uma taxa de sobrevida variando de 10 a 40% em 5 anos [3-5]. 
O câncer de cabeça pescoço é uma doença multifatorial, decorrente de fatores 
ambientais e genéticos. A maioria das alterações genéticas e epigenéticas importantes para o 
desenvolvimento do câncer ocorrem em genes atuantes em vias de sinalização [6-9]. 
O comportamento tumoral, assim como seu prognóstico, pode ser definido 
molecularmente pelo quantitativo e qualitativo destas alterações, incluindo um potencial 
ilimitado de replicação, sinalização da proliferação autossuficiente, habilidade de evadir à 
apoptose, angiogênese, ineficiente reparo do DNA, invasão e metástase [10]. 
A agressividade da doença está diretamente relacionada com a capacidade de 
adaptação da célula tumoral às condições desfavoráveis, ao crescimento da massa tumoral, 
tais como escape da vigília imunológica e sobrevivência em condições de hipóxia, além de 
migração para outras regiões do corpo no desenvolvimento de metástases [11,12]. 
A maior precisão prognóstica do carcinoma epidermóide oral e de orofaringe pode ser 
realizada através de testes moleculares com expectativa de aumento da sobrevida dos 
pacientes em 80%. Estes dados confirmam a importância da investigação do potencial de 
marcadores moleculares para a doença [13,14]. 
Pesquisa envolvendo expressão e polimorfismos de genes que fazem parte de vias 
metabólicas complexas abre perspectiva de melhor compreensão da doença e de novos alvos 
terapêuticos. Dessa forma, o trabalho teve o objetivo de avaliar o potencial das proteínas Fas 
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Cell Surface Death Receptor (FAS), Fas Cell Surface Death Receptor Ligand (FASL), 
Fibroblast growth factor receptor 4 (FGFR4), Leptin Receptor (LEPR), Hypoxia-inducible 
factor 1-alpha (HIF1-a), N-myc downstream regulated gene 1 (NDRG1) e JMJ C-domain-
containing histone demethylase 1A (JMJD1A) e os polimorfismos Gly388Arg no gene 
FGFR4 e Gln223Arg no gene LEPR, como possíveis marcadores moleculares para as 
características clinicopatológicas e o prognóstico de pacientes com o carcinoma epidermóide 
oral e de orofaringe. 
A presente tese será apresentada na seguinte forma: Introdução, com a 
contextualização, importância e objetivos; Revisão da literatura e as respectivas referências 
bibliográficas. A metodologia, bem como os resultados e as discussões serão apresentados na 
forma de artigos que foram publicados ou submetidos para periódicos. 
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2. REVISÃO BIBLIOGRÁFICA 
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2.1. Carcinoma Epidermóide Oral e de Orofaringe 
 
O câncer de cabeça e pescoço é o quarto em incidência e o quinto em mortalidade na 
lista das neoplasias mais frequentes no mundo [1], sendo a sobrevida de 5 anos alcançada por 
apenas 30% dos pacientes com o câncer oral ou de orofaringe [5]. 
No Brasil, estimam-se para que no ano de 2014 sejam detectados 11.280 novos casos 
de câncer oral em homens e 4.010 em mulheres. Tais valores correspondem a um risco 
estimado de 11,54 casos novos a cada 100 mil homens e 3,92 a cada 100 mil mulheres [15]. O 
carcinoma epidermóide é o tipo histológico predominante, ocorrendo em mais de 90% dos 
casos [16]. 
Do ponto de vista epidemiológico, sabe-se que existe uma associação entre o consumo 
de tabaco e o aparecimento de tumores na cavidade oral e orofaringe. O risco de 
desenvolvimento do câncer é de até nove vezes maior em indivíduos tabagistas, do que em 
não tabagistas, mantendo relação direta com a quantidade consumida [13,17]. O uso do álcool 
também é fator de risco para o desenvolvimento do câncer das vias aerodigestivas superiores, 
além de atuar como potencializador dos efeitos carcinogênicos do tabaco [18]. 
Além dos fatores de risco químicos, o carcinoma epidermóide oral e de orofaringe 
pode ser decorrente de infecção por Human Papillomavirus (HPV) ou de fatores de 
suscetibilidade genética [19]. Existe ainda a associação entre a condição socioeconômica do 
paciente e o aparecimento do tumor, essa associação pode ser explicada pela pobreza, 
alimentação deficiente e dificuldade de acesso ao serviço de saúde [20,21]. 
O tratamento do carcinoma epidermóide oral e de orofaringe é frequentemente 
baseado em uma estratégia de multimodalidade terapêutica, envolvendo cirurgia, 
quimioterapia e radioterapia. O planejamento terapêutico e prognóstico da doença é 
estabelecido com base nos parâmetros clínicos, radiológicos e histopatológicos, os quais 
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consistem no local do tumor primário e o sistema de classificação TNM (T - Tumor, N - 
Linfonodo, M - Metástase) [22,23]. 
Apesar dos avanços das técnicas cirúrgicas e do surgimento de novas abordagens 
terapêuticas, a sobrevida média dos pacientes em estágio avançado da doença não tem 
aumentado substancialmente nas últimas décadas. Pacientes portadores de carcinoma 
epidermóide oral e de orofaringe geralmente apresentam um padrão clínico heterogêneo, com 
um prognóstico ruim relacionado ao estágio avançado da doença. Enquanto o tratamento do 
tumor primário e da metástase regional permite um aumento da sobrevida, mais de 50% dos 
pacientes desenvolvem, em um período de cinco anos, recorrência da lesão primária ou 
metástases [24]. 
O tamanho do tumor primário, a presença de metástases linfonodais, margens 
positivas após excisão cirúrgica, têm sido indicadores de uma pior evolução clínica em 
pacientes com carcinoma epidermóide oral e de orofaringe. No entanto, pacientes com 
características clínicas semelhantes podem apresentar padrões diferentes de crescimento e 
evolução tumoral [25]. 
Muitos relatos mostram que as variações nos mecanismos moleculares da ativação 
apoptótica, estímulos da proliferação celular e na resposta às condições de hipóxia estão 
relacionadas com a agressividade e o prognóstico dos pacientes oncológicos [11,12]. Isto 
demonstra a necessidade da análise de outros fatores complementares capazes de nortear com 
maior precisão o tratamento e prognóstico da doença. 
Desta forma estudos nos mecanismos de evasão da apoptose mediada pelo sistema 
imunológico (FAS/FASL), disfunção no controle da proliferação celular (FGFR4), 
proliferação celular facilitada pela ativação angiogênica (LEPR), adaptações celulares como 
resposta à hipóxia tumoral (HIF1-a), ativação do mecanismo de sobrevivência celular 
(NDRG1) e modificações epigenéticas dependentes de hipóxia (JMJD1A) podem oferecer 
caminhos para a descoberta de marcadores moleculares prognósticos. 
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2.2. Evasão da apoptose mediada pelo sistema imunológico: FAS/FASL 
 
Múltiplos fatores são responsáveis pela modulação do crescimento tumoral e 
modulação do prognóstico de pacientes com tumores malignos. Acredita-se que o 
desequilíbrio entre os mecanismos de apoptose e proliferação seja o essencial para o 
desenvolvimento e prognóstico tumoral, podendo fornecer uma previsão mais realista do 
comportamento do tumor [26]. 
A apoptose é um programa de morte celular com função crucial no desenvolvimento e 
homeostase de organismo multicelulares. Este processo complexo envolve muitos genes, 
mutações e polimorfismos, podendo levar à sinalização de morte deficiente, potencializando a 
agressividade tumoral [27]. 
Algumas células tumorais podem adquirir com sucesso a habilidade de resistir ao 
estímulo apoptótico ou de induzir a apoptose de linfócitos tumor específico, favorecendo a 
progressão tumoral [28]. A capacidade de resistir aos estímulos apoptóticos é compartilhada 
por quase todos os tipos de doenças malignas. Modificações nos componentes da via 
apoptótica são associadas ao desenvolvimento do câncer, à agressividade tumoral e ao 
prognóstico dos pacientes [29,30]. 
A apoptose pode ser ativada por duas vias, a intrínseca, também conhecida como via 
mitocondrial, e a extrínseca, também conhecida por via citoplasmática. A via intrínseca ocorre 
através da presença de sinais de estresse intracelular, ativando o apoptossomo executor, com a 
liberação do Citocromo-c do espaço intramembranoso da mitocôndria para o citoplasma. A 
apoptose pela via extrínseca ocorre através de estímulos externos, por meio da ativação de 
receptores específicos presentes na membrana celular denominados receptores da morte. 
Ambas as vias culminam na ativação de proteases conhecidas como caspases executoras, que 
clivam o DNA nuclear levando a célula à morte [31-34]. 
Dentre os oito receptores pertencentes à família de proteínas transmembrânicas do tipo 
1, o FAS, também conhecido como CD95, tem sido extensamente investigado pela sua 
atuação apoptótica, assim como seu ligante, o FASL, alternativamente denominado como 
CD178 [35,36]. 
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Assim como os outros membros de sua família, o FAS é caracterizado por conter três 
domínios extracelulares ricos em cisteína, seguidos por uma região intracelular composta por 
uma sequência de 80 aminoácidos denominada domínio de morte. A molécula é funcional 
apenas depois de oligomerizada em trímero, ação dependente de uma sinalização extracelular 
desencadeada pelo seu ligante FASL [37]. 
O FASL é uma proteína de membrana tipo II e apresenta 281 resíduos de aminoácidos, 
sendo 150 presentes na sua região extracelular e 77 na região citoplasmática. O FASL 
também pode clivado por proteólise, tomando uma forma livre solúvel bioativa [38,39]. 
Logo após a ativação do receptor FAS pelo seu ligante FASL, o sinal apoptótico é 
transmitido por transdução de sinal através da molécula adaptadora intracelular FAS-
associated Death Domain (FADD), que é recrutada por possuir complementação ao domínio 
de morte do receptor FAS. Esta fará a adaptação da forma zimogênica da cisteíno-aspartato 
protease (caspase-8) que sofrerá autoclivagem passando para sua forma ativa, dando início à 
cascata de ativação de diversas outras caspases. Por fim, esta cascata irá culminar na ativação 
da DNAse que irá fragmentar o DNA nuclear entre os nucleossomos, levando à modificações 
morfológicas e bioquímicas características da apoptose, com consequente morte celular 
[32,36,40]. 
Enquanto a expressão do FAS é uma característica comum da maioria dos tecidos não 
neoplásicos, a expressão do FASL é restrita às estruturas anatomicamente bem definidas. 
Além de células do sistema imune, como linfócitos T e células Natural Killers, a expressão 
FASL é constitutiva nas células de Sertoli nos testículos, células epiteliais da câmara anterior 
do olho e células de Kupffer dos sinusóides hepáticos. Estudos revelaram que a expressão do 
FASL nestes sítios confere um privilégio imunológico ao tecido, onde os linfócitos FAS 
positivos são rapidamente destruídos após ligação com FASL [38]. 
O sistema FAS/FASL já demonstrou desempenhar um papel importante na regulação 
da apoptose em células tumorais. Estudos em diversos tipos tumorais indicam que 
imunomodulações causadas pela alteração da expressão do FAS/FASL pode ter um impacto 
significante na sobrevida dos pacientes [40]. 
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A perda ou redução da expressão FAS ocorre frequentemente e progressivamente no 
processo de progressão tumoral em seres humanos. A expressão FAS já foi relatada como 
diminuída em câncer colorretal, esôfago, mama, melanoma, hepático, gástrico e pulmão [39-
43]. 
O baixo índice apoptótico é associado com baixa ou nula expressão FAS e 
consequente piora da sobrevida, sugerindo que a expressão tumoral FAS seja um fator 
biológico importante no controle da doença, mas que é perdido de acordo com a evolução 
tumoral [26]. 
Estudos tem demonstrado que o FASL pode ser expresso por vários tipos de tumores 
sólidos, tais como no câncer de mama [44,45], ovário [46], fígado [47,48], colorretal [49], 
melanoma [50] e em cabeça e pescoço [51,52], frequentemente sendo associado com o pior 
prognóstico. 
Esses resultados sugerem que tumores FASL positivos podem induzir à supressão 
imunológica contra os linfócitos do infiltrado tumoral, representando o modelo de evasão 
imunológica tumoral denominada “contra-ataque” (do inglês, counterattack) [53]. Neste 
modelo, as células tumorais podem, através da expressão FASL, explorar a sinalização 
extrínseca da apoptose para se livrar das células linfocitárias FAS positivas, de modo a 
minimizar seu reconhecimento e combate pelo sistema imunológico [54]. 
Contudo, evidências controversas dificultam a compreensão clara do papel exercido 
pela expressão tumoral FASL, na qual está relacionada com a rejeição tumoral em modelos 
experimentais [55,56]. Colocando em dúvida a capacidade real de tumores malignos 
expressarem FASL [57]. 
Os conflitos de evidências sugerem que a função e expressão FASL podem ser 
diferentes entre os diversos tipos tumorais. No carcinoma epidermóide oral e de orofaringe, a 
relação entre as expressões FAS e FASL e seu prognóstico não é clara, tornando necessário 
este tipo de investigação. 
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2.3. Disfunção no controle da proliferação celular: FGFR4 
 
O câncer é causado por uma série de modificações moleculares na maquinaria 
regulatória celular [58]. Assim como descrito anteriormente, o desequilíbrio entre apoptose e 
proliferação celular é o ponto chave para o desenvolvimento e progressão tumoral [26]. A 
perda do controle da proliferação celular pode ser decorrente da superexpressão ou variações 
genéticas em fatores críticos para o seu bom funcionamento [59]. 
Atuantes no controle da proliferação celular, os membros da família do Receptor do 
Fator de Crescimento de Fibroblasto (FGFR) estão divididos em duas principais classes. A 
primeira composta por FGFRs com baixa afinidade, que necessitam da ligação de moléculas 
de heparano sulfato proteoglicanos na superfície celular para acoplamento de seus ligantes. A 
segunda classe dos FGFRs são as de alta afinidade e englobam os FGFRs de 1 a 4. Cada 
subtipo pode ser diferentemente expresso gerando isoformas, ativadas por ligantes distintos, 
levando à dimerização e fosforilação de resíduo tirosino-quinase na porção citoplasmática da 
célula [11,60,61]. 
Ainda não completamente compreendidas, essas sinalizações são mediadoras de 
processos celulares importantes como proliferação, diferenciação, sobrevida e motilidade, 
ocorrendo principalmente durante o desenvolvimento embrionário. Em adição ao FGFR1 e 
FGFR3, o FGFR4 pode induzir a transformação celular, atuando como oncogenes. [62-64]. 
Estes receptores possuem um papel decisivo no desenvolvimento do câncer e estão 
envolvidos no crescimento da célula tumoral e sua migração [11]. 
Diversos estudos tem examinado o papel do FGFR4 na carcinogênese de diferentes 
tipos tumorais, provendo evidências da complexidade envolvida na via de sinalização 
FGF/FGFR, devido ao grande número de proteínas que interagem diretamente com o FGF e o 
FGFR4 [65-69]. 
No câncer de cabeça e pescoço, a investigação de 104 casos por imunohistoquímica 
apontou a expressão forte FGFR4 relacionada com o pior prognóstico, sugerindo que a maior 
quantidade de proteína FGFR4 pode levar à maior ativação para a proliferação das células 
tumorais [70]. 
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Adicionalmente, trabalhos apontam para alterações genéticas nos genes FGFRs, 
associadas a diversos tumores. A maioria dos SNPs é silenciosa, porém, alguns estão 
diretamente relacionados com a progressão da doença. [61,70]. 
Assim como a expressão FGFR4 tem sido relacionada com diversos aspectos da 
progressão tumoral, a transição de uma Guanina por uma Adenina (G>A) que ocorre no gene 
FGFR4, tem sido associada com a progressão e prognóstico de várias neoplasias como 
sarcomas, mama, próstata, bexiga e de cabeça e pescoço [11,61,70-79]. 
Presente no éxon 9 do gene FGFR4, este polimorfismo resulta na substituição de uma 
glicina (Gly) por uma arginina (Arg) na posição 388 do domínio transmembrânico, localizada 
em uma região hidrofóbica e altamente conservada [59,80]. 
Contudo, o número de evidências que confirmam a importância da expressão FGFR4 e 
o do polimorfismo Gly399Arg na progressão tumoral e prognóstico é insuficiente para um 
consenso final. Adicionalmente, o mecanismo de sinalização FGF/FGFR pode ser variável 
entre os diversos tipos tumorais, tornando incerto o papel do FGFR4 no carcinoma 
epidermóide oral e de orofaringe. 
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2.4. Proliferação celular facilitada pela ativação angiogênica: LEPR 
 
Para o crescimento de tumores sólidos é essencial a manutenção dos níveis de 
oxigênio e nutrientes para que a maquinaria celular esteja em constante funcionamento, sendo 
a falta destes um bloqueio em seu desenvolvimento. A proliferação celular tumoral pode ser 
facilitada por estímulos angiogênicos desencadeados pela ação do hormônio Leptina. Atuando 
no crescimento, proliferação e migração de células endoteliais, a Leptina tem sido associada 
com o surgimento de diversas neoplasias, tais como o câncer de mama, colorretal, fígado e 
próstata [81-83]. 
Esse hormônio atua como mitógeno em diversos tipos de células, como em células 
endoteliais, células musculares lisas, células normais e neoplásicas epiteliais. A Leptina atua 
também no processo de formação de vasos sanguíneos em tecidos normais e neoplásicos, 
atuando como promotora na expressão de genes que promove a angiogênese, resultando no 
aumento da vascularização endotelial [84-86]. 
A Leptina é um hormônio produzido predominantemente pelo tecido adiposo branco, 
responsável pela regulação da massa de tecido adiposo através dos efeitos hipotalâmicos da 
saciedade e gasto de energia [87,88]. Além da regulação da massa corpórea, a Leptina e seu 
receptor estão relacionados com os processos de hematopoiese, formação dos ossos, 
angiogênese, cicatrização, reprodução e resposta imunológica, dentre outras funções ainda em 
estudo [82,89,90]. 
A Leptina atua através de seu receptor, o LEPR. Um receptor transmembrânico da 
família de receptores de citocinas de classe 1, conhecido por estimular a transcrição gênica 
através da ativação citosólica de proteínas Signal Transducer and Activator of Transcription 
(STAT) [88,91,92]. O LEPR é expresso principalmente no hipotálamo, sistema vascular 
humano e em culturas primárias de células endoteliais [93]. 
Quando a Leptina se liga com o seu receptor, ocorre uma mudança na conformação da 
molécula, levando a fosforilação cruzada de moléculas Janus Kinase (JAK) e consequente 
fosforilação das proteínas (STAT). Posteriormente, a STAT transloca-se para o núcleo, onde 
se liga na região promotora de genes alvos da ativação transcricional. Dentre os genes 
13 
 
ativados pela STAT, muitos são enzimas conhecidas por sua atuação no desenvolvimento e 
progressão de diversos tipos tumorais [90,94]. 
O LEPR tem sido frequentemente identificado em células malignas de diferentes 
origens, incluindo o câncer de mama, pulmão, gástrico e leucemias [95-98]. Algumas 
investigações têm relacionado a expressão LEPR com o desenvolvimento, diferenciação e 
prognóstico em câncer de mama e gástrico, sugerindo que sua atuação no controle da 
proliferação celular seja importante nestes aspectos [98-101]. 
A eficiente sinalização via Leptina/LEPR em tumores foi associada à expressão 
aumentada da Matriz Metalloproteinase-9 (MMP-9). Por sua vez, a MMP-9 atua na 
degradação do colágeno tipo IV constituinte da membrana basal, processo relacionado com a 
invasão e metastatização tumoral, sugerindo seu impacto no prognóstico destas neoplasias 
[102]. 
Dentre os diversos polimorfismos descritos no gene LEPR, a transição de uma 
Adenina para uma Guanina leva à troca de uma Glutamina (Gln) para Arginina (Arg) no 
aminoácido 223. Localizado no domínio extracelular do receptor, esta troca de um 
aminoácido neutro por um aminoácido com carga positiva, altera a função e capacidade de 
sinalização do receptor [103,104]. 
O polimorfismo Gln223Arg no gene LEPR foi relacionado com o risco do câncer de 
mama, sendo o risco aumentado nos indivíduos homozigotos para o alelo Arg223 [98]. 
Resultados contrários foram apresentados em estudos com câncer de próstata, onde os 
indivíduos homozigotos para o alelo Gln223 possuem um maior risco de desenvolver esta 
neoplasia [105,106]. 
A primeira investigação deste polimorfismo no câncer de cabeça e pescoço confirma 
sua relação com o desenvolvimento da doença. O autor ainda sugere que seus achados 
reforçam o importante papel do LEPR na promoção do crescimento tumoral angiogênese, 
metástase e invasão tumoral [107]. 
Quando moléculas pró-angiogênicas tem sua expressão aumentada em relação às 
moléculas angiostáticas, o tumor adquire o fenótipo angiogênico que permite a formação de 
novos vasos sanguíneos [108]. 
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A terapia tumoral antiangiogênica representa uma estratégia promissora para o 
tratamento do câncer e provavelmente exibirá potencial clínico conjuntamente com as terapias 
antitumorais clássicas [109]. No entanto, muitos dos mecanismos envolvidos neste processo 
devem ser mais bem esclarecidos de modo a ser utilizado no carcinoma epidermóide oral e de 
orofaringe. 
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2.5. Adaptações celulares como resposta à hipóxia tumoral: HIF1-a 
 
O sistema de resposta celular às condições de hipóxia é essencial para a progressão de 
tumores sólidos [110,111], como por exemplo, os tumores de mama, pulmão, ovário e cabeça 
e pescoço [112-116]. 
A hipóxia é encontrada na maioria dos tumores sólidos devido às alterações estruturais 
e quantitativas nos vasos, levando a diminuição das concentrações de oxigênio [117]. 
Contudo, a hipóxia não é um mecanismo exclusivo da progressão tumoral [118], sendo 
também encontrada durante o desenvolvimento embrionário [119-121] e em doenças 
isquêmicas [122-126]. 
Para manter a homeostase do oxigênio, muitos organismos eucariotos adaptaram 
evolutivamente um mecanismo especializado para reforçar a ingestão e distribuição do 
oxigênio. Consequentemente, uma via responsiva dependente de oxigênio foi conservada e 
presente em quase todas as células de mamíferos [127,128]. 
O complexo transcricional Hypoxia-inducible factor 1 (HIF1) é o principal mecanismo 
de regulação para a homeostase do oxigênio celular e sistêmico [119,127,129-137]. 
Quando ligado ao DNA genômico, o complexo HIF1 pode promover a transcrição de 
mais de 100 genes que atuam em mecanismos específicos para evitar a morte celular causada 
pela hipóxia. Por sua vez, as proteínas produzidas aumentam as concentrações de oxigênio 
através da angiogênese [138], além de enzimas do transporte de glicose e metabolismo 
[116,136]. 
O complexo HIF1 é um fator de transcrição composto por uma subunidade -alpha e 
uma -beta, a última também conhecida como Aryl Hydrocarbon Receptor Nuclear 
Translocator (ARNT), ambas pertencem a família de proteínas basic Helix-Loop-Helix-Per-
ARNT-Sim (bHLH-PAS) [139,140]. 
A subunidade HIF1-beta é expressa constitutivamente, mantendo os seus níveis de 
mRNA e proteína constantes, independente das condições de oxigênio [141]. Igualmente, a 
transcrição e síntese protéica da HIF1-alpha são constitutivas e particularmente não são 
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afetadas pelo teor de oxigênio [139,141-144]. Contudo, sob normóxia, a HIF1-alpha é 
rapidamente degradada quando detectada [139]. 
Assim como as proteínas da família bHLH-PAS, a subunidade HIF1-alpha possui os 
dois domínios bHLH e PAS, necessários para a heterodimerização com a subunidade HIF1-
beta [145]. Mais dois domínios presentes na HIF1-alpha, o N-terminal (N-TAD) e o C-
terminal (C-TAD), localizados nas porções C-terminal e mediana da proteína [146]. 
Outro importante domínio presente na subunidade HIF1-alpha é o Oxygen-regulated 
Degradation (ODD – Degradação regulada por oxigênio), que media sua estabilidade de 
acordo com a disponibilidade de oxigênio [147]. Modificações pós-traducionais, como a 
hidroxilação, acetilação e ubiquitinação no domínio ODD da proteína HIF1-alpha é o 
primeiro passo de sua degradação [148-150]. 
Sob condições normais de oxigênio, a HIF1-alpha é hidroxilada pela proteína Prolyl 
Hydroxylation (PHD) em seu domínio ODD [134,135, 151-155]. Em seguida, a proteína von 
Hippel-Lindau (pVHL) reconhece a hidroxilação adicionando ubiquitina, marcando-a para a 
degradação proteossomal [133,156-162]. 
Alternativamente, a degradação da HIF1-alpha pode ser dada através da acetilação 
pela proteína Acetyltransferase Arrest-defective-1 (ARD1), no resíduo de lisina 532 (Lys532) 
de seu domínio ODD, e consequente ubiquitinação e degradação proteossomal [135,151,163]. 
Sob condição de hipóxia, a subunidade HIF1-alpha é estabilizada e traslocada do 
citoplasma para o núcleo, onde dimeriza com a subunidade HIF1-beta, formando o complexo 
HIF1 trascricionalmente ativo [136,141,164]. 
Entre os genes regulados pela HIF1 importantes para o processo tumorigênico estão os 
fatores angiogênicos, de proliferação celular, transportadores de glicose, enzimas glicolíticas 
anaerobióticas [136,165,166]. O aumento da densidade vascular, a permeabilidade tecidual e, 
consequente diminuição da distância para a difusão do oxigênio são resultados da ativação 
angiogênica, favorecendo a progressão tumoral [161,167]. 
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Em diversos tipos tumorais, a expressão da HIF1-alpha foi associada com o processo 
de carcinogênese e o prognóstico e sobrevida dos pacientes, como por exemplo, no câncer 
renal [168], bexiga [169], colorretal [170], mama [171,172], ovário [173] e útero [174,175]. 
No carcinoma epidermóide de cabeça e pescoço, os trabalhos apontam a expressão 
HIF1-alpha associada à carcinogênese e fatores prognósticos e de sobrevida [176-182], 
porém, sem um consenso entre os trabalhos. Dê um lado, a expressão HIF1-alpha fraca é 
relacionada com a pior sobrevida dos pacientes [177,183], enquanto que outros trabalhos 
sugerem que a pior sobrevida seja determinada pela expressão forte [176,184,185]. 
Os marcadores de hipóxia, como a proteína HIF1-alpha, podem auxiliar na 
estratificação dos pacientes em categorias, facilitando identificar a conduta terapêutica mais 
adequada para cada estrato, assim como predizer o prognóstico com maior precisão [186]. 
Deste modo, a expressão HIF1-alpha é um forte candidato à marcador molecular no 
carcinoma epidermóide oral e de orofaringe, principalmente pelo tratamento destas neoplasia 
visarem, em segundo plano, a preservação da estrutura e função de órgão essenciais para a 
qualidade de vida dos doentes [187]. 
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2.6. Ativação do mecanismo de sobrevivência celular: NDRG1 
 
A hipóxia e a indução da angiogênese são fatores cruciais para a progressão de 
tumores sólidos [110,111]. Nos mais de 100 genes conhecidos por serem alvos do complexo 
HIF, é comum a presença de Elementos Responsivos à Hipóxia (HRE - Hypoxia Response 
Element) em suas sequencias nucleotídicas [138]. 
Um gene que apresenta três motivos HRE em sua sequência e alvo do complexo HIF é 
o N-myc downstream regulated gene 1 (NDRG1) [188,189]. A sequência do gene NDRG1 é 
altamente conservada [190] e está localizada na banda cromossômica 8q24 [191]. O gene 
codifica uma proteína com 394 aminoácidos e geralmente está presente no citoplasma e 
membrana de células epiteliais [192]. 
A proteína codificada pelo gene NDRG1 parece ter um papel no controle do ciclo 
celular, na diferenciação celular e no crescimento, na resposta hormonal e ao estresse, 
podendo atuar como uma proteína sinalizadora entre o citoplasma e o núcleo [193]. 
A expressão NDRG1 também pode ser regulada por outros fatores, como a presença 
de danos no DNA, níquel, androgênio e homocisteína, possivelmente atuando como supressor 
tumoral [194,195]. Estudos funcionais tem relatado que a expressão NDRG1, quando 
induzida por danos no DNA, está associada com a expressão da Protein 53 (p53), sugerindo 
sua cumplicidade na indução da apoptose via p53 [196]. 
Outros trabalhos indicam ainda que a expressão do NDRG1 é regulada pela Sirtuin 1 
(SIRT1), uma proteína com função de promover a sobrevivência celular, com expressão 
aumentada em situações de hipóxia. Neste caso, aumentos nos níveis de NDRG1 reduzem a 
expressão de p53, levando à diferenciação de trofoblastos e diminuição da injúria celular 
[197]. 
O preciso papel do NDRG1 é desconhecido, mas sua proteína parece ser 
multifuncional, com participação em diversas vias moleculares [198]. Diversas evidências 
sugerem o envolvimento da proteína NDRG1 na proliferação e diferenciação celular, atuando 
no papel de supressor tumoral [199,200]. 
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A expressão anormal NDRG1 tem sido observada em diferentes tipos de tumores, em 
algumas vezes associada com o estágio avançado da doença e o prognóstico [188,201-203]. 
Apesar das perspectivas dos resultados de pesquisas, o papel do gene NDRG1 no 
câncer ainda é incerto. Sua relação com a progressão tumoral e o prognóstico em diversos 
tipos tumorais sugere fortemente a atuação do NDRG1 como um mecanismo de sobrevivência 
celular [195], abrindo a possibilidade de considerar o NDRG1 como um potencial alvo de 
diagnóstico, prognóstico ou terapêutico no carcinoma epidermóide oral e de orofaringe. 
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2.7. Modificações epigenéticas dependentes de hipóxia: JMJD1A 
 
O mecanismo de resposta da célula tumoral às condições de hipóxia envolve a 
ativação de mais de 100 genes [204]. Atualmente, pouco se sabe sobre a regulação 
epigenética durante a ativação transcricional gerada pelo sistema HIF [205]. Contudo, as 
adaptações trascricionais mediada pela hipóxia e pelas HIFs (HIF1a, HIF2a, HIF3a e HIF1b) 
sugerem a ocorrência de modificações epigenéticas das histonas [206]. 
Um número crescente de estudos tem identificado o papel da metilação de histonas na 
adaptação tumoral à hipóxia mediada pelo sistema HIF [207-209]. Sabe-se que o sistema HIF 
facilita a adaptação metabólica da célula tumoral por meio da transcrição direta de enzimas 
com atividade desmetilase, como a Jumonji Domain-Containing Protein 1A (JMJD1A) 
[209,210]. 
A JMJD1A regula a expressão de genes pró-angiogênicos induzidos pela hipóxia 
diminuindo a metilação das histonas em suas regiões promotoras. A diminuição do 
crescimento tumoral foi relata em estudo onde a JMJD1A foi silenciada [211]. 
A atuação da proteína JMJD1A consiste na desmetilação de histonas em resíduos de 
lisina e arginina em reação oxigênio dependente, sendo necessários íons de Fe (II) e α-
cetoglutarato como cofatores. Seu alvo de ação são as Lisinas 9 das Histonas H3, dimetiladas 
ou monometiladas (H3K9me2 e H3K9me1) [212]. 
A metilação de histonas contribui para uma mudança na estrutura da cromatina, de 
modo a aumentar ou diminuir a facilidade do acesso de enzimas, podendo influenciar na 
expressão gênica, replicação e reparo do DNA. [213]. 
Um nível baixo da JMJD1A resulta em uma baixa atividade desmetiladora e 
consequentemente, à uma ativação gênica ineficiente. A indução da JMJD1A pela hipóxia 
pode aumentar a atividade das desmetilases de histonas nos promotores de genes alvos, 
podendo levar a célula tumoral à um fenótipo indiferenciado [209]. 
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A perda global de metilação da H3K9 foi observada em muitos tipos de câncer [214]. 
Estas evidências sugerem que a regulação epigenética imposta pelas condições de hipóxia é 
um fator importante para caracterizar a agressividade tumoral [215,216]. 
A expressão da proteína JMJD1A tem sido relacionada com o desenvolvimento e 
prognóstico de diversos tipos de tumores, tais como o câncer colorretal [211], hepatocelular 
[216], nasofaríngeo [217]. 
Com relação ao de câncer de cabeça e pescoço, este tipo de investigação ainda não foi 
consolidada. Dessa forma, é necessário que a JMJD1A seja avaliada com relação ao seu 
potencial em ser um marcador molecular de prognóstico em pacientes com carcinoma 
epidermóide oral e de orofaringe. 
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4.1. Artigo 1: HIF1-alpha expression predicts survival of patients with squamous 
cell carcinoma of the oral cavity 
 
O artigo intitulado “HIF1-alpha expression predicts survival of patients with 
squamous cell carcinoma of the oral cavity” foi publicado em Setembro de 2012, pela revista 
Plos One, a qual possui fator de impacto de 3.73 (JCR2012). 
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ABSTRACT 
Background: Oral squamous cell carcinoma is an important cause of death and morbidity 
wordwide and effective prognostic markers are still to be discovered. HIF1α protein is 
associated with hypoxia response and neovascularization, essential conditions for solid 
tumors survival. The relationship between HIF1α expression, tumor progression and 
treatment response in head and neck cancer is still poorly understood. 
Patients and methods: In this study, we investigated HIF1α expression by 
immunohistochemistry in tissue microarrays and its relationship with clinical findings, 
histopathological results and survival of 66 patients with squamous cell carcinoma of the 
lower mouth. 
Results: Our results demonstrated that high HIF1α expression is associated with local 
disease-free survival, independently from the choice of treatment. Furthermore, high 
expression of HIF1α in patients treated with postoperative radiotherapy was associated with 
survival, therefore being a novel prognostic marker in squamous cell carcinoma of the mouth. 
Additionally, our results showed that MVD was associated with HIF1α expression and local 
disease relapse. 
Conclusion: These findings suggest that HIF1α expression can be used as a prognostic 
marker and predictor of postoperative radiotherapy response, helping the oncologist choose 
the best treatment for each patient. 
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INTRODUCTION 
Head and neck cancer is a significant cause of mortality and morbidity worldwide, 
presenting approximately 600,000 new cases yearly [1], whereas tumors of the oral cavity 
show 389,000 new cases per year, with a mortality rate of 50% [2]. 
Currently, the most important prognostic factor is the presence of regional lymph node 
metastases, which correlates with a 50% reduction in life expectancy [2-4]; however, 
micrometastases may not be detected by routine histology [5]. 
Oral squamous cell carcinoma is a solid tumor that relies on a hypoxia cellular 
response system for tumor progression [6-12]. Focal hypoxia is found in the majority of solid 
tumors due to quantitative and qualitative alterations in tumor vasculature, leading to local 
reduction of oxygen availability [13]. 
Tumoral response to radiotherapy has been studied through hypoxia measurements in 
cervical cancer, as well as other tumors, including head and neck tumors [14, 15]. Hypoxia-
inducible factor-1 (HIF1) is a heterodimeric transcriptional complex that functions as the 
main regulator of systemic and cellular oxygen homeostasis [16-25]. When activated, HIF1 
can induce the transcription of over 60 genes, as an attempt to avoid hypoxia-mediated dell 
death. Among HIF1-regulated genes, there are angiogenic and proliferating factors, glucose 
transporters, anaerobic glycolytic enzymes and others, that are important for tumorigenesis 
[25-28]. 
Expression of HIF1α has been studied in renal, bladder, colorectal, breast, ovary and 
cervical tumors and it was often associated with patient prognosis [29-36]. Positive HIF1α 
expression has been associated with improved prognosis in head and neck tumor patients that 
underwent surgery [37]. Additionally, Fillies and cols, described a better prognosis for 
patients with high HIF1α expression in squamous cell carcinomas of the tongue basis treated 
with radiotherapy [38]. Nonetheless, lower survival and higher disease relapse in irradiated 
patients has been associated with strong HIF1α protein expression, as reported by Aebersold 
et al. [39]. These contradicting results indicate a high complexity of the hypoxia signaling 
pathway and its participation in radiotherapy treatment response. 
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A tempting hypothesis to explain these observations would envision HIF1α activation 
as an inducer of higher tumor vascularization and oxygenation due to Vascular Endothelial 
Growth Factor (VEGF) expression [40], which would ultimately increase the concentration of 
intratumoral reactive oxygen species after radiotherapy and therefore render such tumors 
more responsive to this type of therapy. 
In this study, we demonstrate that high HIF1α expression is associated with local 
disease-free survival. Moreover, in patients treated with postoperative radiotherapy, high 
HIF1α expression was associated with survival, therefore being a novel prognostic marker in 
squamous cell carcinoma of the oral cavity. We also show that microvessel density (MVD) is 
associated with HIF1α expression and local disease relapse. These findings suggest that 
HIF1α expression can be used as a prognostic marker and a tool for choosing the best 
treatment for each patient. 
 
MATERIALS AND METHODS 
Ethics 
The present study was approved by the Ethics Committee of the Heliopolis Hospital 
on 06/10/2008 (CEP # 619). 
 
Sample 
Samples were collected by the Head and Neck Genome Project (GENCAPO), a 
collaborative consortium created in 2002 with more than 50 researchers from 9 institutions in 
São Paulo State, Brazil, whose aim is to develop clinical, genetic and epidemiological 
analysis of head and neck squamous cell carcinomas. In this study, we analyzed 66 
parafinized tumor samples of squamous cell carcinomas of the lower mouth, surgically treated 
in the Head and Neck Surgery Department of the Heliópolis Hospital, São Paulo, Brazil, 
during the period of January/2001 to December/2007. Exclusion criteria were: previous 
surgical or chemotherapy treatment, presence of distant metastasis, no removal of cervical 
lymph nodes and positive surgical margins. 
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Postoperative radiotherapy was indicated when the tumor invaded adjacent tissues 
(pT4) or cervical lymph nodes were compromised (pN+). Histopathologycal characteristics of 
all samples were revised by A.M.C.M. (pathologist,author) of the Heliópolis Hospital. 
According to TNM classification (3
rd
 edition) [41], 27 tumors were T1 and T2, 13 tumors 
were T3 and 26 tumors were T4. Thirty six cases showed metastasis to cervical lymph nodes. 
Well differentiated tumors were found in 30 samples, moderately differentiated tumors in 31 
and poorly differentiated in 5 (Table 1). 
A gender and age characterization of the 66 patients showed a predominance of males 
(85%) and age varying from 34-81 years, with a mean age of 55 years. According to the 
anatomical localization of the tumor, 26 (39.4%) were on the tongue, 12 (18.2%) on inferior 
gums, 22 (33.3%) on the floor of the mouth and 6 (9.1%) on the retromolar area (Table 1). 
Postoperative radiotherapy was indicated for 36 patients, but 3 deceased before the 
end of treatment and were excluded from the survival after radiotherapy analysis. After a 
follow up of at least 24 months, 36 patients (54.5%) were alive, 27 (41.0%) died due to the 
disease and 3 (4.5%) died of other causes. Local reccurrence was observed in 23 cases 
(34.8%). 
 
Tissue microarray 
Formalin-fixed, paraffin-embedded tissue sections from 66 primary oral squamous 
cell carcinomas treated at the Head and Neck Surgery Department of Heliópolis Hospital, 
São Paulo, SP, were used for immunohistochemistry (IHC) analysis. Histological 
characterization of all samples was done by Hematoxylin and Eosin staining, followed by 
immunohistochemistry analysis of tissue microarrays (TMA). Two 1mm cylinders taken 
from tumor central regions were used to represent each sample in the TMA slide (Beecher 
Instruments
®
, Silver Spring, MD, USA). 
 
Immunohistochemistry 
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Anti-HIF1α polyclonal antibody (Millipore Corporation®, USA) was used in the IHC 
reaction, at a 1:150 dilution [42-44]. Positive (breast cancer controls) and negative (absence 
of primary antibody) controls were used. Sample scoring was performed by semi-quantitative 
microscopic analysis, considering the number of stained cells and signal intensity. Two spots 
were evaluated for each sample and a mean score was calculated. Considering the percentage 
of HIF1α immune-positive tumor cells, a score of 1 was given when ≤10% of cells were 
positive; 2 when 10-50% of cells were positive and 3 when ≥50% of cells were positive. 
Signal intensity was scored as negative (0), weak (1), moderate (2) and strong (3). Both scores 
were multiplied [45, 46] and the resulting score was used to categorize HIF1α expression as 
negative (≤1), weak (1-6) and strong (>6). 
Angiogenic activity was assessed by MVD analysis using anti-CD34 antiboby (Santa 
Cruz Biotecnology
®
, USA) for the IHC reaction, at a 1:150 dilution. Endothelial cell 
cytoplasmic staining was considered the positivity criterion. MVD was scored in four areas of 
the tissue array and categorized as ≤20, 20-40 and >40%. These analyses were performed by 
A.M.C.M. (pathologist, author). 
 
Statistical Analysis 
The chi square and Fisher exact tests were used for association analysis and 
confirmation was obtained by the Lilliefors test (significance considered when p < 0.05). 
Multivariate logistic regression was used to obtain odds ratio (OR) and confidence intervals 
(CI ≥ 95%). Survival was calculated by the number of months between surgery and death for 
each patient or the last appointment in case patients were alive. In order to calculate disease-
free survival, the time endpoint was the date of local disease relapse. The Kaplan-Meier 
model was used for survival analysis, using the Wilcoxon p-value and the Cox Proportional 
Hazards to adjust p-values and obtain hazard ratio (HR). Statistical calculations were 
performed using the Epi Info
®
 v3.4.3, 2007 and Statsoft Statistica
®
 v7.0.61.0 softwares. 
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RESULTS 
HIF1α expression was detected in all 66 tumors. However, expression was considered 
weak in 34 samples (51.5%), strong in 32 (48.5%) and it did not show association with tumor 
characteristics, such as size (p=0.284), positive lymph nodes (p=0.787) and others (Table 1). 
In spite of being more frequent in surviving cases, strong expression of HIF1α did not 
show a significant correlation with the status alive (p=0.094), but showed a significant 
association with cases with no local disease relapse (p=0.002, Table 2). Multivariate analysis, 
considering pTNM, showed that HIF1α weak expression is an independent marker for local 
disease relapse, representing an increased risk of over 7 times in relation to strong expression 
(OR=7.59, CI=1.94-29.75). 
Although overall survival did not show a significant association with HIF1α 
expression intensity (p=0.185), a strong expression was associated with local disease-free 
survival (p=0.013, Figure 1). According to a 12 month after surgery follow up, approximately 
10% of cases with high HIF1α expression showed local disease relapse, as compared to 
approximately 50% of relapse in patients with low HIF1α expression (Figure 1). Multivariate 
analysis, considering pTNM, revealed that a weak expression of HIF1α is an independent 
marker for a faster local disease relapse, with a 3-fold increased risk when compared to strong 
expression (HR=3.22, CI=1.16-8.93). 
HIF1α low expression was associated with increased local disease relapse, 
independently from the choice of treatment (p=0.038 for operated and irradiated patients; 
p=0.039 for operated, but not irradiated patients), increasing the risk of relapse 11 times, both 
for operated and irradiated patients, as well as operated, but not irradiated cases (OR=11.47 
for operated and irradiated patients; OR=11.48 for operated, but not irradiated patients. 
pTNM was considered in both analysis). 
Most interestingly, when analyzing patients that undertook postoperative radiotherapy, 
low HIF1α expression correlated with a six-fold increased risk of death when compared to 
high expression (OR=6.13, IC=1.18-31.94, p=0.031, considering pTNM). In contrast, 
surgically treated patients that did not make use of postoperative radiotherapy did not show 
this association (p=0.366). Moreover, patients treated only with surgery showed no survival 
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or local disease relapse difference between cases with high or low expression of HIF1α 
protein (Figure 2b and Figure 2d). 
Disease-free survival curves of patients treated with postoperative radiotherapy 
showed that half of the cases with low expression of HIF1α deceased in the first 12 months 
after surgery, as compared to less than 10% of death in the same period for patients with high 
HIF1α expression (Figure 2a). Multivariate analysis, considering pTNM, showed that weak 
expression of HIF1α is an independent prognostic marker, indicating a 3-fold increased risk of 
death for patients treated with postoperative radiotherapy (HR=3.41, 1.13-10.34, p=0.029). 
Microvessel density was associated with HIF1α expression in operated and irradiated 
cases (p=0.036), as well as with lower local disease relapse (p=0.001, Table 3). 
 
DISCUSSION AND CONCLUSIONS 
HIF1α protein expression was observed in all squamous cell carcinomas of the lower 
mouth, being divided into weak and strong expression signals, according to semiquantitative 
immunohistochemistry staining suggested by Soini et al. [45] and modified by Campos et al. 
[46]. 
Our analysis showed a significant relationship between strong HIF1α protein 
expression and lower local disease relapse (p=0.002) and increased local disease-free survival 
(p=0.013), suggesting that weak HIF1α expression is an independent risk factor for local 
disease relapse. Similarly, we have shown a correlation between strong HIF1α protein 
expression and disease-free survival (Figure 2a, p=0.015) and local disease-free survival for 
patients that undertook postoperative radiotherapy (Figure 2c, p=0.005). Interestingly, surgery 
only cases did not show a correlation between HIF1α protein expression and disease-free 
survival (p=0.700) or local disease-free survival (p=0.391), suggesting an interaction between 
tumor vascularization and radiotherapy response. Because, no significant relationship 
between HIF1α expression and tumor size was found, we propose HIF1α expression as a 
TNM-independent prognostic marker. 
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Beasley et al. [37] and Fillies et al. [38] have described strong HIF1α protein 
expression as an independent marker for higher disease-free survival, as well as general 
survival in patients with head and neck squamous cell carcinomas. 
In contrast, lower survival and higher disease relapse has been associated with strong 
HIF1α protein expression, as reported by Aebersold et al. [39]. However, his work analyzed 
radiotherapy treated squamous cell carcinomas of the oropharynx, a disease also associated 
with HPV and therefore with different characteristics [1]. 
Lin and cols. have described an association between strong HIF1α expression and 
lower survival in patients with oral squamous cell carcinomas [47]. In this case, 
immunohistochemistry was quantitative and the scores based on nuclear staining (strong 
signal attributed to over 60% of immunopositivity). Koukourakis et al. observed a relationship 
between HIF1α and HIF2α high protein expression and a more aggressive local disease or 
worse response to carboplatin chemotherapy in squamous cell carcinomas of the tongue, 
pharynx and larynx [48]. In 2008, a study by Koukourakis et al. showed a relation between 
HIF1α expression and local disease control in irradiated advanced head and neck tumors, but 
they did not find the same relation with HIF2α expression [49]. This observation might be 
explained by the fact HIF1α e HIF-2α can have different functions and tissue specificity, as 
HIF1α and HIF-2α knockout mice show different phenotypes [50, 51]. Above all, the authors 
attributed their findings to a higher tumor vascularization. 
According to Astekar et al., MVD is directly related with VEGF expression and 
vascularization of HNSCCs [52]. We have observed that high HIF1α expression is related to 
higher MVD, probably as a result of VEGF pathway activation, according to previous reports 
[40]. Moreover, we have detected a correlation between MVD and local disease relapse in 
patients that underwent post operative radiotherapy. These results suggest that the best disease 
control is achieved when angiogenesis is stimulated by HIF1α and VEGF expression. 
Hypoxia is commonly found in human solid tumors, serving as a selective 
environment for survival of aggressive cancer cells and as protection from anti-cancer 
therapies. Commonly, hypoxic tumors are resistant to radio and chemotherapies, since these 
treatments rely upon the generation of oxygen reactive species to induce lethal DNA damage 
[53, 54]; however, Zolzer and Streffer [55] showed an increased radiosensitivity of some 
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human tumor cell lines under chronic hypoxia conditions, including squamous cell carcinoma 
cell lines. This observation was probably due to breakdown of cellular energy metabolism and 
cessation of cell cycle progression [55]. 
In comparison, tumors with high expression of HIF1α activate transcription of genes 
associated with angiogenesis, such as VEGF, therefore it would be reasonable to predict a 
higher success rate for postoperative radiotherapy in conditions where tissue oxygen 
concentrations and its reactive species are high, causing a more efficient neoplastic cell death. 
It has been shown that increased vascularization of solid tumors can result in higher 
oxygenation, which together with increased radionuclide uptake show great potential for 
optimizing treatment strategies, causing better tumor response to therapy [56]. 
This hypothesis is in complete accord with our results. We propose that head and neck 
tumors with high HIF1α expression are more sensitive to radiotherapy due to the facilitated 
generation of reactive oxygen species in a more vascularized microenvironment. 
In conclusion, we suggest the utilization of HIF1α protein expression as a squamous 
cell carcinoma tumor marker to better evaluate the therapeutic options at hand, especially in 
the decision of postoperative radiotherapy and the establishment of local disease relapse 
prognosis. For instance, a low expression of HIF1α could indicate the need of more extensive 
surgical margins. We also suggest that a single immunohistochemistry scoring protocol is 
adopted, so that results are similarly interpreted worldwide. 
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FIGURE LEGENDS 
Figure 1. Local disease-free survival relation to HIF1α expression. High HIF1α 
expression is related to an increased local disease-free survival. 
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Figure 2. HIF1α expression and specific or local disease-free survival after treatment. 
Considering surgical (S) treatment only, high HIF1α expression predicts local disease-free 
survival. Considering surgery plus radiotherapy (S+RT), high HIF1α expression predicts both 
specific and local disease-free survival. 
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TABLES 
Table 1. Correlation of tumor epidemiological and pathological features with HIF1α 
expression. 
Features 
Frequency 
 HIF1α expression 
 Weak Strong 
p value 
No. (%)  No. (%) No. (%) 
Gender         
Female 10 (15.2)  ─ ─ ─ ─ ─ 
Male 56 (84.8)  ─ ─ ─ ─ ─ 
Age, yr (median 55, df ±10,9)         
≤ 55 33 (50.0)  ─ ─ ─ ─ ─ 
> 55 33 (50.0)  ─ ─ ─ ─ ─ 
Treatment         
Only operated 33 (50.0)  ─ ─ ─ ─ ─ 
Operated and irradiated 33 (50.0)  ─ ─ ─ ─ ─ 
Site         
Tongue 26 (39.4)  ─ ─ ─ ─ ─ 
Inferior gums 12 (18.2)  ─ ─ ─ ─ ─ 
Floor of the mouth  22 (33.3)  ─ ─ ─ ─ ─ 
Retromolar area 6 (9.1)  ─ ─ ─ ─ ─ 
Stage         
I+II 16 (24.3)  8 (23.5) 8 (25.0) 
0.394 III 15 (22.7)  10 (29.4) 5 (15.6) 
IV 35 (53.0)  16 (47.1) 19 59.4) 
Tumor size (pT)
*
         
pT1, pT2 27 (40.9)  14 (41.2) 13 (40.6) 
0.284 pT3 13 (19.7)  9 (26.4) 4 (12.5) 
pT4 26 (39.4)  11 (32.4) 15 (46.9) 
Lymph node status (pN)
*
         
Absent 30 (45.5)  16 (47.1) 14 (43.8) 
0.787 
Present 36 (54.5)  18 (52.9) 18 (56.2) 
Differentiation grade         
Well 30 (45.4)  20 (58.8) 10 (31.2) 
0.079 Moderately 31 (47.0)  12 (35.3) 19 (59.4) 
Poorly 5 (7.6)  2 (5.9) 3 (9.4) 
Lymphatic invasion         
Absent 21 (31.8)  11 (32.4) 10 (31.3) 
0.923 
Present 45 (68.2)  23 (67.6) 22 (68.7) 
Perineural invasion         
Absent 31 (47.0)  17 (50.0) 14 (43.3) 
0.611 
Present 35 (53.0)  17 (50.0) 18 (56.7) 
Total 66 (100.0)  34 (51.5) 32 (48.5)  
*TNM classification (3
rd
 edition). 
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Table 2. HIF1α expression association with the status alive or local disease relapse. 
Prognostic features 
HIF1α Expression 
Weak Strong 
p value 
No. (%) No. (%) 
Survival status      
Alive 15 (46.9) 21 (67.7) 
0.094 
Deceased 17 (53.1) 10 (32.3) 
Local disease relapse      
No 14 (43.7) 23 (82.1) 
0.002 
Yes 18 (56.3) 5 (17.9) 
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Table 3. Microvessel density relation to HIF1α expression and local disease relapse in 
operated and irradiated patients. 
Microvessel density 
HIF1α expression  Local disease relapse 
Weak Strong 
p value 
 No Yes 
p value 
No. (%) No. (%)  No. (%) No. (%) 
≤ 20 4 (26.7) 0 (0) 
0.036 
 0 0 4 (50) 
0.001 20 - 40 10 (66.7) 10 (66.7)  16 (72.7) 4 (50) 
> 40 1 (6.7) 5 (33.3)  6 (27.3) 0 (0) 
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4.2. Artigo 2: Prognostic significance of NDRG1 expression in oral and 
oropharyngeal squamous cell carcinoma 
 
O artigo intitulado “Prognostic significance of NDRG1 expression in oral and 
oropharyngeal squamous cell carcinoma” foi publicado em Setembro de 2012, pela revista 
Molecular Biology Reports, a qual possui fator de impacto de 2.506 (JCR2012). 
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ABSTRACT 
Human N-myc downstream-regulated gene 1 (NDRG1) is a metastasis suppressor gene with 
several potential functions, including cell differentiation, cell cycle regulation and response 
to hormones, nickel and stress. The purpose of this study was to investigate the 
immunoexpression of NDRG1 in oral and oropharyngeal squamous cell carcinomas 
searching for its role in the clinical course of these tumors. We investigated 
immunohistochemical expression of NDRG1 protein in 412 tissue microarray cores of tumor 
samples from 103 patients with oral and oropharyngeal squamous cell carcinomas and in 110 
paraffin-embedded surgical margin sections. The results showed NDRG1 up-regulation in 
101/103 (98.1%) tumor samples, but no expression in any normal tissue sample. Western 
blot assays confirmed the immunohistochemical findings, suggesting that lowerleves of 
NDRG1 are associated with a high mortality rate. NDRG1 overexpression was related to 
long-term specific survival (HR=0.38; p=0.009), whereas the presence of lymph-node 
metastasis showed the opposite association with survival (HR=2.45; p=0.013). Our findings 
reinforce the idea that NDRG1 plays a metastasis suppressor role in oral and oropharyngeal 
squamous cell carcinomas and may be a useful marker for these tumors. 
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INTRODUCTION 
The human N-myc downstream-regulated gene (NDRG) family includes four 
members (NDRG1-4) and belongs to the / hydrolase superfamily [1-4]. Because the 
catalytic triad residues in the NDRG proteins differ from the consensus on conventional 
hydrolases, they do not appear to have hydrolytic properties [5]. In spite of not presenting a 
common functional motif, these proteins share well-conserved residues [3,4] and have been 
detected in different species of metazoa, such as zebrafish, as well as in plants [6,7]. There are 
several reports suggesting that they are involved in cell proliferation and differentiation. 
NDRG1 and 2 have a potential role as tumor suppressors [8,9]. 
The human NDRG1 gene, also named DRG1, CAP43, GC4 or RTP, has been mapped 
to chromosome band 8q24.3 [10], the same region where MYC is located and frequently 
amplified in cancer [11,12], including head and neck squamous cell carcinomas [13]. 
Mutations in NDRG1 have been described as the cause of the Lom form of hereditary motor 
and sensory neuropathy, also called Charcot-Marie-Tooth disease type 4D (MIM 601455). 
The 5’ region of the gene exhibits a CpG island, suggesting that NDRG1 may be regulated by 
DNA methylation. Experiments using histone deacetylase inhibitors as well as the analysis of 
the promoter region have shown that epigenetic mechanisms [8,14] and different transcription 
factors, such as MYC, also participate in the regulation of this gene [15,16]. 
Although ubiquitously expressed, NDRG1 is mostly observed in epithelial cells. 
Immunohistochemical and electron microscopy studies have shown that the protein has 
cytoplasmatic or nuclear localization depending on the tissue and is also associated with 
membranes, especially close to adherens junctions [17]. 
Human N-myc downstream-regulated gene 1 protein can be regulated by nickel, has a 
molecular weight of 43 kDa and contains 394 aminoacids [18], with a C-terminal region that 
is unique for the presence of three 10-amino acid tandem repeats [3]. The protein has 
phosphorylation sites for protein kinase A and decreased levels of phosphorylated forms have 
been related to low cell densities, linking NDRG1 to proliferation [19,20]. 
Several biological functions have been attributed to NDRG1, including differentiation 
[1,21], cell cycle regulation [22,23], maintenance of the myelin sheaths [24], vesicular 
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transport and recycling of the adhesion molecule E-cadherin [25], response to hormones [20] 
and stress, such as heavy metal [18], hypoxia [26,27] and DNA damage response [22]. 
Human N-myc downstream-regulated gene 1 transcript and protein have been reported 
downregulated in most tumors, especially in advanced stages, such as in breast, esophageal 
and colorectal cancers [1,28,29]. In prostate cancer, some studies have detected NDRG1 
upregulation in neoplastic cells compared with normal cells [30,31], downregulation in 
advanced stages [22,32] or different expression patterns, probably reflecting differences in the 
response to hypoxia and androgens [33]. NDRG1 upregulation has also been observed in 
melanoma, as well as in lung, brain, liver, breast, renal, cervical and oral cancers [30,34-38]. 
The latter are very common malignancies which have been associated with high mortality and 
morbidity rates, mainly due to late diagnosis [39]. This disease has an unpredictable course 
and no sensitive biomarkers of aggressive behavior have been established. At the moment, the 
most important prognostic factor is the presence of regional lymph node metastases. 
However, micrometastases may not be detected by routine histology [40], making the 
identification of new efficient markers of diagnosis and prognosis an urgent necessity [41]. 
Motivated by our previous study findings showing NDRG1 upregulation in head and 
neck tumors [35], we investigated the immunoexpression of NDRG1 in primary oral and 
oropharyngeal squamous cell carcinomas and matched normal tissues, searching for the 
relationship between the expression of this protein and the clinical course of the disease. 
 
MATERIAL AND METHODS 
Case selection 
Formalin-fixed, paraffin-embedded tissue sections from 137 primary carcinomas and 
110 non-neoplastic mucosas were obtained from 103 patients with oral and oropharyngeal 
squamous cell carcinoma at the Head and Neck Surgery Department of Hospital Heliópolis 
and Hospital do Câncer Arnaldo Vieira de Carvalho, São Paulo, SP, between 2005 and 2007, 
and used for immunohistochemical analysis. A different subset of samples was analyzed by 
Western blot (17 oral squamous cell carcinomas and 7 non-neoplastic surgical margins) from 
17 patients with surgically resected tumors at Hospital do Câncer Arnaldo Vieira de Carvalho, 
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São Paulo, SP. The samples were classified by the TNM system [42]. Both subsets of samples 
were collected by the Head and Neck Genome Project (GENCAPO), a collaborative 
consortium created in 2002 with more than 50 researchers from nine institutions in São Paulo 
State, Brazil, whose aim is to develop clinical, genetic and epidemiological analysis of head 
and neck squamous cell carcinomas. 
Cases with a positive histology report of oral and oropharyngeal squamous cell 
carcinoma from two different hospitals were included in the study. Histopathological slides 
were reviewed by senior pathologists to confirm the diagnosis and select appropriate areas for 
immunohistochemical and Western blot. Lip tumors were excluded because of their origin 
and characteristics. 
The average age of the patients was 55.8 years (SD 24, range, 81 years), and the 
male/female sex ratio was 6:1. Most patients were smokers or former smokers (95.8%) and 
had a history of chronic alcohol abuse (85.0%; Table 1). The choice of treatment depended on 
tumor size and presence of metastases and included surgery, radiation therapy and/or systemic 
chemotherapy. The clinical follow-up was at least 48 months after surgery. 
The study protocol was approved by the National Committee of Ethics in Research 
(CONEP 1763/05, 18/05/2005) and informed consent was obtained from all patients enrolled. 
 
Tissue microarray  
The tissue microarray (TMA) included 103 formalin-fixed, paraffin-embedded 
samples. For each case, one representative tumor area was selected from a hematoxylin- and 
eosin-stained section of a donor block. Four cylinders per tumor (diameter of 1 mm each) 
were punched out and arrayed in a recipient paraffin block using an arraying device (Beecher 
Instruments, Silver Spring, MD, USA). Therefore, the TMAs contained 412 cores of tumor 
samples.  
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Immunohistochemical analysis 
Immunohistochemical analyses of TMA tumor specimens and of usual paraffin 
surgical margin blocks were performed using conventional protocols [43-47]. 
Sections of the tissue microarray block and the individual paraffin-embedded blocks 
were immunostained with antibody against NDRG1. Briefly, after deparaffinization in xylene 
and rehydration in graded ethanol, antigen epitope retrieval was performed using 10 mM 
citrate buffer, pH 6.0 in a vapor cooker. Endogenous peroxidase activity was blocked with 3% 
hydrogen peroxide for 15 min. 
Primary goat anti-NDRG1 polyclonal antibody (SC-19464, Santa Cruz Biotechnology, 
Inc, Santa Cruz CA, USA), diluted 1:500, was incubated overnight at 8ºC followed by 
addition of the secondary antibody and streptavidin-horseradish peroxidase (LSAB+, code 
k0690, Dako, CA, USA). Reaction product color was developed by 3,3'-diaminobenzidine 
(DAB, Dako) and counterstaining was performed with Harris hematoxylin. 
The primary antibody was absent in negative controls and a normal prostate sample 
was used as positive control. The immuno-expression of NDRG1 was graded subjectively as 
<50% of positive cells (low NDRG1 immunostaining) and 50% of positive cells (high 
NDRG1 immunostaining). Expression differences were evaluated between cases showing low 
and high immunostaining. 
 
Protein extraction  
Fresh samples of primary oral and oropharyngeal carcinomas and matched surgical 
margins were frozen in liquid nitrogen and stored at -80C. Analysis of hematoxylin and 
eosin-stained sections indicated that each carcinoma sample contained at least 70% tumor 
cells and the corresponding surgical margins were free of tumor cells. After RNA extraction 
using TRIzol
®
LS Reagent (Invitrogen Corporation, CA, USA), total protein was extracted by 
100% isopropyl alcohol, 0.3 M guanidine hydrochloride in 95% ethanol, 100% ethanol, and 
1% SDS. Protein concentration was determined with a BCA™ Protein Assay kit (Pierce, 
Rockford, IL, USA). 
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Western blot 
Antibodies used were monoclonal antibody anti-NDRG1 (N-19:SC-19464, Santa Cruz 
Biotecnology), diluted 1:200, and monoclonal anti-β-Actin antibody diluted 1:1000 (Santa 
Cruz Biotecnology). In brief, protein samples (60 ug) were loaded onto 10% SDS-
polyacrilamide gels. The molecular weight ladder was the BenchMark™ Ladder 
(Invitrogen,). The proteins were then transferred electrophoretically (Mini Protean, BioRad, 
CA, USA) to PVDF paper (Hybond, GE Healthcare Bio-Science, NJ, USA). After blocking, 
the PVDF membranes were incubated with anti-NDRG1 (Santa Cruz Biotechnology), 
followed by washing and incubation with the secondary antibody anti-goat horseradish 
peroxidase HRP-conjugated (Santa Cruz Biotechnology). SuperSignal West Pico 
Chemiluminescent Substrate (Pierce, Rockford, IL, USA) was used for detection. 
 
Statistical analysis 
The chi square and Fisher exact tests were used for association analysis and 
confirmation was obtained by the Lilliefors test (significance considered when p < 0.05). 
Multivariate logistic regression was used to obtain odds ratio and confidence intervals (CI ≥ 
95%). Survival analysis was performed through Kaplan-Meier curves and log-rank test, and 
predictors of cancer-specific survival were analyzed by Cox multiple regression. Statistical 
calculations were performed using the Epi Info® v3.4.3, 2007 and Statsoft Statistica® 
v7.0.61.0 softwares. 
 
RESULTS 
Immunohistochemical analysis was performed in 412 TMA cores of tumor samples 
from 103 patients with oral and oropharyngeal squamous cell carcinomas. One hundred and 
ten samples of surgical margins were also studied in sections of individual paraffin-embedded 
blocks. Figure 1 presents immunohistochemical staining for NDRG1 in non-tumoral and 
tumoral cells of these carcinomas. 
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The results showed drastic differences between immunopositive cell counts means for 
normal and tumor areas. A total of 101/103 tumor samples showed positive immunostaining 
(Fig.1a), mostly in cytoplasm (81/101 or 80.2%; Table 2). However, no expression was 
detected in any surgical margin (Fig. 1b). 
Human N-myc downstream-regulated gene 1 expression was evaluated with respect to 
clinicopathological factors, to estimate the potential use of NDRG1 as a prognostic marker in 
oral cancer. However, no correlation between NDRG1 protein expression and TNM, degree 
of differentiation and other clinicopathological features was observed (Table 3). 
When considering low (11.9%) and high (88.1%) NDRG1 expression level groups 
(total: 101 patients), the results suggested that low NDRG1 levels are associated with a high 
mortality rate (9 deaths/10 cases) and, conversely, high NDRG1 levels with low mortality (42 
deaths/91 cases). Additionally, low NDRG1 levels are associated with a statistically 
significant shorter global (p=0.004) and specific survival (p=0.001). 
The Kaplan-Meier survival curves showed better specific survival for those patients 
with high NDRG1 expression (log-rank=0.001; Fig. 2). Multivariate survival analysis using 
Cox’s regression model indicated that NDRG1 expression and nodal metastasis were 
independent prognostic factors for survival. As expected, NDRG1 overexpression was related 
to long-term specific survival (HR=0.38; p=0,009), whereas the presence of lymph node 
metastasis showed the opposite association (HR=2.45; p=0.013; Table 4). 
Human N-myc downstream-regulated gene 1 expression western blot results for 17 
oral squamous cell carcinomas and seven non-neoplastic surgical margins are presented in 
Figure 3. As observed in the immunohistochemical analysis, surgical margins were negative 
for NDRG1 expression, whereas mostly tumors showed high levels of this protein. 
 
DISCUSSION 
The NDRG1 protein is expressed in most epithelial cells [17], where it may act on 
differentiation [1,21], cell cycle regulation [22,23], and response to stress [18,22]. This 
protein has phosphorylation sites for protein kinase A and phosphorylated forms have been 
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linked to proliferation [19,20]. These data as well as the fact that abnormal expression of 
NDRG1 has been observed in different tumors, sometimes associated with advanced 
carcinoma stages [30,34,35,37], opens the possibility of considering NDRG1 a potential 
target for cancer diagnosis, prognosis or therapy. 
In this study, we have extended and elaborated on our previous observation that 
NDRG1 is overexpressed in oral cancer [35] and analyzed 412 TMA cores of tumor samples 
from 103 patients with oral and oropharyngeal squamous cell carcinomas and 110 paraffin 
surgical margin sections, as well as 24 fresh samples of these tumors. The results showed 
sharp differences between normal and tumor tissues. In fact, no expression of this protein was 
detected in surgical margins; however, almost all tumors revealed consistent expression of 
NDRG1. Although no correlation between expression and clinicopathological features was 
detected, higher levels of NDRG1 were related to long-term specific survival, whereas nodal 
metastasis showed the opposite association. These findings suggest that NDRG1 plays a 
metastasis suppressor role, a hypothesis previously proposed by Guan et al. [8]. These authors 
found that NDRG1 inhibited in vitro invasion and in vivo colon cancer metastasis, probably 
by inducing
 
cell differentiation. The data of Bandyopadhyay et al. [48] also support the idea 
that NDRG1 is a metastasis suppressor protein since it inhibits the invasive ability of tumor 
cells by downregulating ATF-3, a transcription factor with proinvasive and prometastatic 
effects. 
In contrast, NDRG1 downregulation has been detected in breast, esophageal and 
colorectal cancers [1,28,29,32]. In prostate cancer, the results are controversial since under 
and overexpression have been described [22,30-33], which may be an adaptative response to 
different levels of hypoxia and androgens. 
Supporting our findings, NDRG1 upregulation has been observed in melanoma, lung, 
brain, liver, breast, renal, cervical and pancreatic cancers [30,36-38]. In our previous study 
[35], increased NDRG1 mRNA levels in head and neck normal and neoplastic tissues were 
detected after a detailed informatics analysis of more than 134,000 ORESTES followed by 
experimental validation. In another study, Chang et al. [34], using a differential display 
technique, identified NDRG1 overexpression in oral cancer and correlated with poorer 
differentiation. Moreover, this gene has been observed to be upregulated during keratinocyte 
differentiation in vitro studies and in mouse skin carcinogenesis [1,21]. Unfortunately, we 
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could not confirm this correlation, although a higher frequency of tumors in the present 
analysis showed NDRG1 overexpression and moderate to poor differentiation. 
Similarly to the findings of other authors [17], NDRG1 exhibited predominantly 
cytoplasmatic localization but was also found in the nuclei. Sugiki et al [49] demonstrated 
that NDRG1 interacts with the heat shock cognate protein 70 (Hsc70) and the complex moves 
from the cytosol to the nucleus after cell activation, supporting the idea that NDRG1 performs 
critical functions in the nucleus, acting as a transcription regulator, displaying antitumoral 
effects or causing a cell cycle arrest at the G0/G1 transition [8,22,38,48]. 
To our knowledge, this is the first study assessing NDRG1 expression in a large set of 
oral and oropharyngeal carcinomas, including intracellular distribution, except for Chang et 
al. [34] studying 20 cases of oral carcinomas. As suggested by these authors, NDRG1 
overexpression may indicate a response of tumor cells to stress conditions, such as hypoxia or 
other stimuli, in an attempt to improve cell survival. Although many data have been published 
on NDRG1, its role in molecular pathways is not completely defined. Our study may facilitate 
the understanding of oral and oropharyngeal tumorigenesis, as well as clinical management of 
these carcinomas. 
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FIGURE LEGENDS 
Fig. 1 Immunohistochemical analysis of tumoral areas strongly express NDRG1 in nuclei 
and cytoplasm (400x) (a) and Negative immunostaining for NDRG1 in tumoral and non-
tumoral areas (100x) (b). 
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Fig. 2 Kaplan-Meier specific survival curves for patients with head and neck tumors showing 
low and high NDRG1 expression. 
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Fig. 3 Representative Western blots illustrating the NDRG1 expression in a subset of oral 
squamous cell carcinomas (T) and matched non-neoplastic surgical margins (M) by using 
anti-NDRG1. β-actin was used as an internal control. 
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TABLES 
Table 1. Distribution of 120 patients with oral and oropharyngeal squamous cell carcinoma 
by gender, age, smoking behaviour, alcohol consumption, tumor size, lymph-node and 
distant metastasis. 
Clinicopathological features Number (%) 
Site  
Oral cavity 93 (77.5%) 
Oropharynx 27 (22.5%) 
Gender  
Males 103 (85.8%) 
Females 17 (14.2%) 
Age (years)  
< 40 5 (4.2%) 
40 – 49 33 (27.5%) 
50 – 59 45 (37.5%) 
60 – 69 26 (21.7%) 
≥ 70 11 (9.2%) 
Smoking behavior  
Never smokers 5 (4.2%) 
Former smokers 22 (18.3%) 
Smokers 93 (77.5%) 
Alcohol consumption  
Never drinkers 18 (15.0%) 
Past drinkers 34 (28.3%) 
Current drinkers 68 (56.7%) 
Tumor size  
T1 5 (4.2%) 
T2 41 (34.2%) 
T3 27 (22.5%) 
T4 47 (39.2%) 
Lymph-node metastasis  
Absent (N-) 44 (36.6%) 
Present (N+) 76 (63.3%) 
Distant Metastasis  
Absent (M-) 118 (98.3%) 
Present (M+) 2 (1.7%) 
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Table 2 Frequency of immunoreactivity for NDRG1 in normal and primary tumor cells. 
NDRG1 expression 
Surgical margin (n=110) Tumor (n=103) 
Number (%) Number (%) 
Immunoreactivity level 
  
Negative 110 (100%) 2 (1.9%) 
Low 0 (0%) 12 (11.7%) 
High 0 (0%) 89 (86.4%) 
Nucleus 
  
Negative 110 (100%) 81 (80.2%) 
Positive 0 (0%) 20 (19.8%) 
Cytoplasm 
  
Negative 110 (100%) 20 (19.8%) 
Positive 0 (0%) 81 (80.2%) 
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Table 3 Comparison of NDRG1 immuno-expression in relation to histopathological 
characteristics of 103 head and neck tumors. 
Histopathological characteristics 
NDRG1 expression (n=101) 
 
Level 
p value 
Localization 
p value 
Low High Nuclear Cytoplasmic 
Tumor size (T) 
  
0.494 
  
0.494 
T1 0 5 
 
2 3 
 
T2 4 27 
 
5 26 
 
T3 1 21 
 
3 19 
 
T4 5 38 
 
10 33 
 
Lymph node status 
  
0.152 
  
0.574 
Absent (N-) 2 33 
 
8 27 
 
Present (N+) 8 58 
 
12 54 
 
Differentiation 
  
0.496 
  
0.315 
Poorly 0 8 
 
0 8 
 
Moderately 5 47 
 
12 40 
 
Well 5 35 
 
8 32 
 
Not available* 0 1 
 
1 0 
 
Vascular infiltration 
  
0.467 
  
0.318 
Negative 9 81 
 
17 73 
 
Positive 1 9 
 
3 7 
 
Not available* 0 1 
 
0 1 
 
Lymphatic invasion 
  
0.483 
  
0.543 
Negative 3 26 
 
6 23 
 
Positive 7 65 
 
14 58 
 
Not available* 0 0 
 
0 0 
 
Perineural invasion 
  
0.554 
  
0.257 
Negative 4 40 
 
7 37 
 
Positive 6 50 
 
13 43 
 
Not available* 0 1 
 
0 1 
 
Inflammatory infiltration 
  
0.484 
  
0.470 
Negative – mild 5 33 
 
9 29 
 
Moderate – severe 5 57 
 
11 51 
 
Not available* 0 1 
 
0 1 
 
Desmoplasia 
  
0.210 
  
0.482 
Mild 4 34 
 
8 30 
 
Moderate 0 28 
 
3 25 
 
Severe 1 15 
 
2 14 
 
Not available* 5 14 
 
7 12 
 
* Not available (not considered in the statistical calculations). 
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Table 4 Cox regression analysis of survival for head and neck carcinomas (n=101) evaluating 
the low and high NDRG1 expression, and absence (N-) and presence (N+) of lymph-node 
metastasis. 
 
Number Adjusted hazard ratio Confidence interval (95%) p value 
NDRG1 expression 
    
Low 10 1.00 
  
High 91 0.38 0.18 – 0.79 0.009 
Lymph-node status 
    
Absent (N-) 35 1.00 
  
Present (N+) 66 2.45 1.21 – 4.91 0.013 
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4.3. Artigo 3: FGFR4 profile as a prognostic marker in squamous cell carcinoma 
of the mouth and oropharynx 
 
O artigo intitulado “FGFR4 profile as a prognostic marker in squamous cell 
carcinoma of the mouth and oropharynx” foi publicado em Novembro de 2012, pela revista 
Plos One, a qual possui fator de impacto de 3.73 (JCR2012). 
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ABSTRACT 
Background: Fibroblast growth factor receptor 4 (FGFR4) is a member of a receptor tyrosine 
kinase family of enzymes involved in cell cycle control and proliferation. A common single 
nucleotide polymorphism (SNP) Gly388Arg variant has been associated with increased tumor 
cell motility and progression of breast cancer, head and neck cancer and soft tissue sarcomas. 
The present study evaluated the prognostic significance of FGFR4 in oral and oropharynx 
carcinomas, finding an association of FGFR4 expression and Gly388Arg genotype with tumor 
onset and prognosis. 
Patients and methods: DNA from peripheral blood of 122 patients with oral and 
oropharyngeal squamous cell carcinomas was used to determine FGFR4 genotype by PCR-
RFLP. Protein expression was assessed by immunohistochemistry (IHC) on paraffin-
embedded tissue microarrays. 
Results: Presence of allele Arg388 was associated with lymphatic embolization and with 
disease related premature death. In addition, FGFR4 low expression was related with lymph 
node positivity and premature relapse of disease, as well as disease related death. 
Conclusion: Our results propose FGFR4 profile, measured by the Gly388Arg genotype and 
expression, as a novel marker of prognosis in squamous cell carcinoma of the mouth and 
oropharynx. 
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INTRODUCTION 
The fibroblast growth factor receptor (FGFRs) family comprises structurally related 
tyrosine kinase receptors (FGFR1-4) involved in signaling via interactions with fibroblast 
growth factors (FGFs), playing an important role in a wide range of biological processes, 
including differentiation, proliferation, cell motility and angiogenesis [1,2]. Most FGFs have 
mitogenic activity in a variety of systems, including cell growth, differentiation and migration 
[1]. The proliferative capacity of FGFs is a function of FGFRs, to which they bind and 
through which they signal. 
Deregulation in FGF/FGFR signaling has been implicated in human malignant 
diseases [3-6]. Functional studies demonstrated that FGFR4 interferes in signaling events 
leading to normal cell adhesiveness and corresponding invasive properties of pituitary tumors 
[7]. Although the molecular basis of this function is still a matter of intense research, FGFR4 
seems to play a role in a broader range of human cancers [7-9]. 
A single nucleotide polymorphism (SNP) in exon 9 results in an amino acid change 
(substitution of a glycine residue for an arginine - Gly388Arg) within FGFR4 transmembrane 
domain and a positive correlation with prognostic parameters in several human cancers, 
including breast, colon, lung, prostate and head and neck cancers [7,9-14]. Nevertheless, the 
association between the Gly388Arg genotype and cancer prognosis is not yet clear [15-18], 
especially in head and neck squamous cell carcinomas (HNSCC). 
HNSCC ranks among the top ten most common cancers worldwide, with a large 
incidence variation according to sex and geographical location [19]. No biomarkers are 
currently available for HNSCC patients; prognosis depends largely on the stage at 
presentation, with the most important prognostic factor being the presence of neck node 
metastases [20]. 
To our knowledge, there is a lack of studies suggesting the prognostic significance of 
FGFR4 SNP genotype in HNSCC [9,12]. Streit et al [9] evaluated 104 paraffin-embedded 
tumors and concluded that high expression of FGFR4 together with the Arg388 allele is 
associated with poor clinical outcome. In comparison, da Costa Andrade et al [12] presented 
results claiming an association between the FGFR4 Arg388 allele and shortened survival in 
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75 HNSCC patients. Given the small number of patients with tumors of different primary 
sites evaluated in these studies and the controversial involvement of FGFR family in human 
cancers, we decided to further investigate the impact the Gly388Arg polymorphism in 
HNSCC. 
The present study evaluated the prognostic significance of FGFR4 expression and the 
Gly388Arg genotype in oral and oropharynx carcinomas in regard to tumor onset and 
prognosis. Possible correlations with clinicopathological and prognosis parameters were also 
analyzed. 
 
MATERIALS AND METHODS 
Ethics 
This study was approved by the Committee of Ethics in Research of the Heliopolis 
Hospital on 07/12/2005 (CEP # 402) and an informed consent was obtained from all patients 
enrolled. 
 
Samples 
Samples were collected by the Head and Neck Genome Project (GENCAPO), a 
collaborative consortium created in 2002 with more than 50 researchers from 9 institutions in 
São Paulo State, Brazil, whose aim is to develop clinical, genetic and epidemiological 
analysis of HNSCC. In this study, 122 DNA and 75 tumoral tissue samples were obtained and 
used for polymorphism Gly388Arg genotyping and immunohistochemical analysis of the 
FGFR4 gene, respectively, within a total of 125 patients with oral and oropharyngeal 
squamous cell carcinomas, surgically treated at the Head and Neck Surgery Department of 
Heliópolis Hospital and Arnaldo Vieira de Carvalho Câncer Hospital, São Paulo, Brazil, 
during the period of January/2002 to December/2007. The clinical follow-up was at least 48 
months after surgery. Previous surgical treatment, distant metastasis, no removal of cervical 
lymph nodes and positive surgical margins were exclusion criteria. Histopathological slides 
were reviewed by a senior pathologists to confirm the diagnosis and select appropriate areas 
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for Immunohistochemical analysis. Tumors were classified according to the TNM system 
[21]. Clinical, epidemiological and pathological characteristics of tumors are described in 
Table 1. 
 
Genotyping 
Genomic DNA was extracted from peripheral blood samples of 122 patients as 
previously described [22]. Genotypes were determined by polymerase chain reaction 
restriction fragment length polymorphism (PCR-RFLP). FGFR4 exon 9 was amplified using 
primers described by Bange et al, [8] and analyzed for Gly388Arg polimorfism (rs351855). 
Selected primers were 5´ - GAC CGC AGC AGC GCC CGA GGC CAG - 3´ and 5´ - AGA 
GGG AAG AGG GAG AGC TTC TG - 3’ (Life Technologies, Inc®, São Paulo, SP, Brazil), 
which produce a 168-base pair (bp) fragment. PCR conditions were: a 25-L reaction mixture 
containing 200ng of genomic DNA, 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 200 M of each 
deoxyribonucleoside 5´ triphosphates, 1.5 mM de MgCl2, 1 U Taq DNA polimerase (Life 
Technologies, Inc®, Rockville, MD, USA) and 25 pmol of each primer. PCR initiated with a 
melting step of 5 minutes at 94C, followed by 35 cycles of 1 minute at 94C, 1 minute at 
58°C and 1 minute at 72C. PCR products were digested overnight with BstNI following the 
manufacturer’s instructions (New England Biolabs®, Berverly, MA, USA). Restriction 
fragments were resolved on a 12% non-denaturing polyacrylamide gel. SNP Arg388 in 
FGFR4 gene was characterized by two distinctive fragments of 82 and 27 bp, whereas the 
FGFR4 Gly388 wild-type allele was identified by a single fragments of 109bp. 
 
Tissue microarray 
Tissue microarrays were made using buffered formalin-fixed paraffin-embedded tissue 
sections from 75 primary oral and oropharyngeal squamous cell carcinomas treated at the 
Head and Neck Surgery Department of Heliópolis Hospital, São Paulo, SP, were used for 
immunohistochemistry (IHC) analysis. Histological characterization of all samples was done 
by Hematoxylin and Eosin staining, followed by immunohistochemistry analysis of tissue 
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microarrays (TMA). Two 1mm cylinders were used to represent each sample in the TMA 
slide (Beecher Instruments
®
, Silver Spring, MD, USA). 
 
Immunohistochemistry 
Anti-FGFR4 monoclonal antibody (Santa Cruz Biotechnology
®
, USA) was used in the 
IHC reaction, at a 1:400 dilution [23-25]. Positive (lung control) and negative controls 
(absence of primary or secondary antibody) were used for reaction quality control. Sample 
scoring was performed by semi-quantitative microscopic analysis, considering the number of 
stained tumor cells and signal intensity. Two spots were evaluated for each sample and a 
mean score was calculated. Considering the percentage of FGFR4 immune-positive tumor 
cells, a score of 1 was given when ≤10% of cells were positive; 2 when 10-50% and 3 when 
≥50% of cells were positive. Signal intensity was scored as negative (0), weak (1), moderate 
(2) and strong (3). Both scores were multiplied [26,27] and the resulting score was used to 
categorize FGFR4 expression as negative (≤3), low (>3 and <7) and high (>7). 
 
Statistical Analysis 
The chi square and Fisher exact tests were used for association analysis and 
confirmation was obtained by the Lilliefors test (significance considered when p<0.05). 
Multivariate logistic regression was used to obtain odds ratio (OR) and confidence intervals 
(CI≥ 95%). Survival was calculated by the number of months between surgery and death for 
each patient or the last appointment in case the patient was alive. In order to calculate disease-
free survival, the time endpoint was the date of disease relapse. The Kaplan-Meier model was 
used for survival analysis, using the Wilcoxon p-value and the Cox Proportional Hazards to 
adjust p-values and obtain hazard ratio (HR). Statistical calculations were performed using the 
Epi Info
®
 v3.4.3, 2007 and Statsoft Statistica® v7.0.61.0 softwares. Genotype correlation 
with certain biological variables such as age and gender were not analyzed because we could 
not find biological justifications for these analyses. 
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RESULTS 
FGFR4 Gly388Arg Genotype 
Regarding the SNP Gly388Arg, 66 (54.1%) cases were genotyped as Gly/Gly (wild 
type allele), 47 (38.5%) as Gly/Arg and 26 (7.4%) as Arg/Arg. Allele and genotype 
frequencies were in Hardy-Weinberg equilibrium. 
The Gly388Arg polymorphism did not show a significant association with tumor size 
(p=0.993), positive lymph nodes (p=0.262) and differentiation grade (p=0.700), but was 
significantly associated with lymphatic embolization (p=0.022, Table 1). Multivariate analysis 
showed that presence of at least one allele Arg388 is an independent marker for lymphatic 
embolization (OR=3.88, CI=1.14-13.13, Table 2). 
The Gly388Arg polymorphism was significantly associated with disease specific death 
(p=0.008, Table 1) and multivariate analysis showed that presence of Arg388 allele is an 
independent death risk factor, increasing risk 6 times when compared to absence of this allele 
(OR=6.88, CI=1.64-28.87, Table 2). Nevertheless, the Gly388Arg polymorphism was not 
correlated with disease relapse (p=0.110, Table 1). 
Although disease-free survival did not show a significant association with FGFR4 
polymorphisms (p=0.130), presence of the Arg388 allele was associated with disease specific 
survival (p=0.020). According to a 36 month after surgery follow up, approximately 25% of 
cases with the Gly/Gly genotype died of disease specific causes, as compared to 
approximately 55% of deaths in patients with the Arg388 allele (Figure 1b). Multivariate 
analysis revealed that the presence of Arg388 allele is an independent marker of disease 
specific death, with a 3 fold increased risk when compared with absence of this allele 
(HR=3.26, CI=1.40-7.58, Table 3). 
 
FGFR4 expression 
FGFR4 expression was detected in 75 tumors, being classified as high in 26 (34.7%) 
samples and low in 49 (65.3%) (Figure 2a and 2b, respectively. No samples were negative for 
FGFR4 expression. FGFR4 expression did not show a significant association with tumor 
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characteristics such as size (p=0.051) and differentiation grade (p=0.062), but was 
significantly associated with positive lymph nodes (p=0.036, Table 1). Multivariate analysis 
showed that low FGFR4 expression is an independent marker for lymph node positivity 
(OR=3.81, CI=1.12-12.98, Table 2). FGFR4 expression did significantly correlate with 
disease relapse (p=0.037) and disease specific death (p=0.013, Table 1). Multivariate analysis 
showed that FGFR4 low expression is an independent marker of disease relapse and disease 
specific death, representing an increased risk of over 6 times for both, in relation to high 
expression (respectively, OR=6.73, CI=1.63-27.85 and OR=6.86, CI=1.45-32.40, Table 2). 
Disease-free and disease specific survival were significantly correlated with FGFR4 
expression (p=0.044 and p=0.034, respectively). According to a 24 month after surgery follow 
up, approximately 60% of cases with low expression died of disease specific causes, as 
compared to approximately 30% of deaths in patients with high expression of FGFR4 (Figure 
1c). Additionally, according to a 36 month after surgery follow up, approximately 50% of 
cases with low expression presented disease relapse, as compared to approximately 20% of 
recurrence in patients with high expression of FGFR4 (Figure 1d). Multivariate analysis 
revealed that a low expression of FGFR4 is an independent marker for a faster disease relapse 
and disease specific death, with a 3 fold increased risk when compared to high expression 
(respectively, HR=3.26, CI=1.44-7.37 and HR=3.26, CI=1.21-8.74, Table 3). 
 
FGFR4 Risk Profiles 
In an attempt to combine genotype and expression results, we categorized the FGFR4 
profile in three classes: low risk (high expression and absence of Arg388 allele); intermediate 
risk (high expression and presence of Arg388 allele or low expression and absence of Arg388 
allele) and high risk (low expression and presence of Arg388 allele). Frequencies of each 
FGFR4 profile were 11 (15.5%), 43 (60.6%) and 17 (23.9%), respectively for low, 
intermediate and high risk. 
Disease-free and disease specific survival were significantly correlated with FGFR4 
profiles (p=0.002 and p<0.001, respectively). According to a 24 month after surgery follow 
up, all cases classified as high risk had relapsed and approximately 80% died of disease 
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specific causes, as compared to approximately 30% of recurrence and no deaths of patients 
classified as low risk (Figure 1e and 1f). Multivariate analysis revealed that the high risk 
category is an independent marker for a faster disease relapse and disease specific death, with 
a 4.5 and 13 fold increased risk, respectively, when compared to the low risk profile 
(HR=4.50, CI=1.37-14.82 and HR=12.90, CI=1.54-107.69). 
 
DISCUSSION AND CONCLUSIONS 
FGFR4 belongs to the family of fibroblast growth factor receptors (FGFR1-4), 
transmembrane proteins with tyrosine kinase activity. Multiple signal transduction cascades 
are initiated after binding of FGF ligand to the extracellular domain of the receptor, ultimately 
resulting in gene expression changes [1,2]. FGFRs have been shown to play important roles in 
several processes of embryonic development and tissue homeostasis. Their abnormal 
expression or mutation can cause diverse pathologies, ranging from morphogenetic disorders 
to cancer [28]. This is a group of proteins of considerable interest in cancer biology, because 
they regulate essential processes, including mitogenic and angiogenic activity, having 
important roles in cell differentiation, development, proliferative signaling and motility 
[2,29,30]. 
Several studies have examined the role of FGFR4 in carcinogenesis, providing 
evidences for the complexity of FGF/FGFR signaling pathways in different tumor types 
[7,31-33]. 
Although the presence of FGFR4 Arg388 allele has been shown to indicate a poor 
prognosis in several tumors [8,10,11,34], the mechanism by which it affects cancer 
progression remains unclear. This might be related to signaling cascades that control cell-
matrix adhesion and angiogenesis [35]. 
Although some mechanisms have been described in the literature, the influence of 
Gly388Arg polymorphism in tumor aggressiveness may differ in specific tumors. 
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Our study revealed that low FGFR4 expression in the presence of Arg388 allele is 
associated with worse survival in patients with oral and oropharyngeal squamous cell 
carcinoma. 
Seitzer, et al, [36] verified, using an animal model, that low protein expression, even 
in the presence of FGFR4 Arg388 polymorphism, is related to increased pathway activity. 
This may be explained by the activation of alternative proteins in the signaling cascade or 
other cascades. 
Recently, it has been reported that the presence of polymorphism Gly388Arg is 
associated with increased cancer risk and progression of pituitary tumors through recruitment 
of STAT3 signaling cascade. Activation of this cascade can result in deregulation of cell 
proliferation and apoptosis, leading to tumor progression [37]. Signaling hiperactivation by 
specific mutations depends on their resistance to negative feedback loops [38]. In addition, 
several ubiquitylation proteins bind directly to RTKs altering receptor activation [39]. RTK 
Ubiquitylation may promote receptor degradation creating an important negative feedback 
mechanism [40,41]. 
FGFR4 388Arg has not been consider an oncogene per se, but rather collaborate with 
oncogenes involved in cell motility and invasiveness [36]. 
Our findings may have important therapeutic implications, because inhibition of one 
intracellular pathway may lead to activation of parallel signaling pathways, thereby 
decreasing the effectiveness of single-agent targeted therapies [42]. In support of our 
hypothesis, the Arg388 allele was associated with resistance to adjuvant therapy in breast 
cancer [43]. 
Ansell et al, [44], were the first researchers to report that the Gly388 allele showed a 
significantly higher risk of developing cancer, proposing the Gly388 allele as a risk allele for 
head and neck cancer. 
In contrast, Streit et al, [9] reported that in head and neck SCC, expression of Gly388 
FGFR4 had no impact on disease progression. In another study, da Costa Andrade et al, [12] 
observed that the presence of at least one Arg allele was significantly correlated with reduced 
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overall survival and an increased mortality risk of 2.2. In a recent study, Tanuma et al, [35] 
reported that FGFR4 Arg388 allele was strongly associated with poor prognosis. 
In the present study, we have shown that allele Arg388 is associated with lymphatic 
embolization and premature disease related death. Furthermore, low expression of FGFR4 is 
related to lymph node positivity and premature disease relapse and death in patients with SCC 
of the mouth and oropharynx. 
Based on these results, we have classified patients with low FGFR4 
expression/Arg388 as high risk for relapse and death. In contrast, high FGFR4 
expression/Arg388-negative patients were considered at low risk. In conclusion, we propose 
FGFR4 profile as a novel prognostic marker in SCC of the mouth and oropharynx. 
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FIGURE LEGENDS 
Figure 1. Survival plots. a. and b.: Disease-free survival and disease specific survival 
according to FGFR4 Gly388Arg polymorphism; c. and d.: Disease-free survival and disease 
specific survival according to FGFR4 expression; e. and f.: Disease-free survival and disease 
specific survival according to FGFR4 profile. 
 
 
  
113 
 
Figure 2. Immunohistochemical analysis of tumors. (a) strong FGFR4 expression; (b) 
weak FGFR4 expression. Magnification was 400x. 
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TABLES 
Table 1. Epidemiological, clinical and pathological tumor features and their association with 
Gly388Arg polymorphism and FGFR4 expression. 
Epidemiological, clinical 
and pathological features 
FGFR4 
Genotype Gly388Arg  Expression level 
Total 
Gly/Gly 
Gly/Arg 
+ 
Arg/Arg 
p 
 Total 
Low High p 
No. (%)  No. (%) 
Gender            
Male 106 (86.9) ─ ─ ─  62 (82.7) ─ ─ ─ 
Female 16 (13.1) ─ ─ ─  13 (17.3) ─ ─ ─ 
Age, yr            
median 54, df ±10.2            
Smoker 98 (80.3) ─ ─ ─  54 (72.0) ─ ─ ─ 
Alcoholic 74 (60.7) ─ ─ ─  42 (56.0) ─ ─ ─ 
Treatment            
Only operated 43 (35.2) ─ ─ ─  34 (45.3) ─ ─ ─ 
Operated + irradiated 79 (64.8) ─ ─ ─  41 (54.7) ─ ─ ─ 
Tumor sities            
Oral cavity 87 (71.3) ─ ─ ─  60 (80.0) ─ ─ ─ 
Oropharynx 35 (28.7) ─ ─ ─  15 (20.0) ─ ─ ─ 
Tumor size (T)            
T1+T2 48 (39.3) 26 22 0.993  29 (38.7) 18 11 0.051 
T3 31 (25.4) 17 14   19 (25.3) 9 10  
T4 43 (35.3) 23 20   27 (36.0) 22 5  
Lymph nodes            
Absent 59 (48.4) 35 24 0.262  31 (41.3) 16 15 0.036 
Present 63 (51.6) 31 32   44 (58.7) 33 11  
Differentiation            
Well 47 (38.5) 24 23 0.700  32 (42.7) 24 8 0.062 
Moderately 65 (53.3) 37 28   35 (46.7) 18 17  
Poorly 9 (7.4) 4 5   7 (9.3) 6 1  
Not available 
a
 1 (0.8)     1 (1.3)    
Lymphatic embolization            
Negative 54 (44.3) 35 19 0.022  26 (34.7) 21 5 0.034 
Positive 66 (54.1) 29 37   49 (65.3) 28 21  
Not available
 a
 2 (1.6)     0 (0.0)    
Perineural invasion            
Negative 63 (51.6) 31 32 0.386  39 (52.0) 24 15 0.526 
Positive 56 (45.9) 32 24   35 (46.7) 24 11  
Not available
 a
 3 (2.5)     1 (1.3)    
Disease specific death            
No 55 (45.1) 37 18 0.008  40 (53.3) 21 19 0.013 
Yes 44 (36.0) 18 26   31 (41.4) 25 6  
Not available
 a
 23 (18.9)     4 (5.3)    
Disease relapse            
No 44 (36.1) 29 15 0.110  33 (44.0) 17 16 0.037 
Yes 56 (45.9) 28 28   40 (53.3) 30 10  
Not available
 a
 22 (18.0)     2 (2.7)    
Total 122 (100.0) 66 56   75 (100.0) 49 26  
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a
 Not available (not considered in the statistical calculations). 
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Table 2. Multivariate analysis of the relationship between clinical and pathological tumor features with gene polymorphism and FGFR4 
expression. 
Variables 
Multivariate analysis 
Lymphatic embolization  Lymph-nodes  Disease relapse  Disease specific death 
OR (95% CI) 
a
 P value 
b
  OR (95% CI) 
a
 P value 
b
  OR (95% CI) 
a
 P value 
b
  OR (95% CI) 
a
 P value 
b
 
            
FGFR4 expression            
High 1   1   1   1  
Low 0.46 (0.13-1.68) 0.245  3.81 (1.12-12.98) 0.032  6.73 (1.63-27.85) 0.009  6.86 (1.45-32.40) 0.015 
FGFR4 genotype Gly388Arg            
Gly/Gly 1   1   1   1  
Gly/Arg+Arg/Arg 3.88 (1.14-13.13) 0.029  1.88 (0.60-5.83) 0.276  3.57 (0.99-12.91) 0.052  6.88 (1.64-28.87) 0.008 
Tumor size (T)            
T1+T2 1   1   1   1  
T3 2.00 (0.45-8.84) 0.358  1.38 (0.36-5.22) 0.640  3.13 (0.67-14.57) 0.147  2.67 (0.52-13.78) 0.241 
T4 1.12 (0.30-4.23) 0.859  3.16 (0.86-11.59) 0.083  1.11 (0.28-4.33) 0.885  2.31 (0.57-9.39) 0.242 
Differentiation            
Well 1   1   ─ ─  ─ ─ 
Moderately 2.77 (0.83-9.18) 0.094  2.98 (0.90-9.88) 0.075  ─ ─  ─ ─ 
Poorly 5.70 (0.47-69.08) 0.171  3.91 (0.35-43.15) 0.266  ─ ─  ─ ─ 
Lymph nodes            
Absent ─ ─  ─ ─  1   1  
Present ─ ─  ─ ─  7.69 (1.21-49.00) 0.031  9.44 (1.52-58.65) 0.016 
Irradiated            
No ─ ─  ─ ─  1   1  
Yes ─ ─   ─ ─   0.07 (0.01-0.50) 0.008   0.39 (0.07-2.18) 0.286 
a, b
 Values adjusted by multivariate logistic regression. 
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For Gly388Arg and FGFR4 expression correlation with lymphatic embolization and lymph node status, tumor size and differentiation status were 
considered in the multivariate analysis. For disease relapse and disease specific death, tumor size, lymph node status and radiotherapy treatment 
were considered. 
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Table 3. Multivariate analysis of disease specific survival. 
Variables 
Cox proportional 
Disease-free survival  Disease-specific survival 
HR (95% CI) 
a
 P value 
b
  HR (95% CI) 
a
 P value 
b
 
      
FGFR4 expression      
High 1   1  
Low 3.26 (1.44-7.37) 0.005  3.26 (1.21-8.74) 0.019 
FGFR4 genotype Gly388Arg      
Gly/Gly 1   1  
Gly/Arg+Arg/Arg 1.77 (0.85-3.67) 0.124  3.26 (1.40-7.58) 0.006 
Tumor size (T)      
T1+T2 1   1  
T3 3.53 (1.46-8.52) 0.005  3.35 (1.13-9.92) 0.029 
T4 1.99 (0.85-4.69) 0.115  1.65 (0.64-4.26) 0.304 
Lymph nodes      
Absent 1   1  
Present 2.62 (1.05-6.53) 0.039  4.80 (1.56-14.73) 0.006 
Irradiated      
No 1   1  
Yes 0.22 (0.09-6.53) 0.002   0.48 (0.18-1.27) 0.139 
a, b
 Values adjusted by Cox proportional hazards. 
Tumor size, lymph node status and radiotherapy treatment were considered in the 
multivariate analysis. 
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4.4. Artigo 4: FAS/FASL expression profile as a prognostic marker in 
squamous cell carcinoma of the oral cavity 
 
O artigo intitulado “FAS/FASL expression profile as a prognostic marker in 
squamous cell carcinoma of the oral cavity” foi publicado em Julho de 2013, pela 
revista Plos One, a qual possui fator de impacto de 3.73 (JCR2012). 
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ABSTRACT 
FAS/FASL altered expression may cause tumor protecting immunomodulation, with a 
direct impact on patient prognosis. FAS expression was studied in 60 squamous cell 
carcinomas of the oral cavity. FAS expression did not show a significant association 
with tumor histopathological characteristics, but was significantly associated with 
lymph node positivity. FAS expression was significantly associated with disease 
specific death and negative FAS expression was an independent risk factor, increasing 
risk 4 times when compared to positive expression. When FAS and FASL expression 
results were combined, we were able to define high, intermediate and low risk profiles. 
Disease-free and disease-specific survival were significantly correlated with FAS/FASL 
expression profiles. The high risk category was an independent marker for earlier 
disease relapse and disease-specific death, with approximately 4- and 6-fold increased 
risk, respectively, when compared to the low risk profile. Risk profiles based on 
FAS/FASL expression showed that high risk was significantly associated with increased 
disease relapse and death, as well as shorter disease-free or disease-specific survival. 
This categorization, added to patient clinical data, may facilitate the choice of therapy, 
minimizing treatment failure and increasing disease control. 
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INTRODUCTION 
Head and neck cancer (HNC) is a significant cause of mortality and morbidity 
worldwide, presenting approximately 600,000 new cases yearly [1], whereas tumors of 
the oral cavity contribute with 389,000 new cases per year, with a mortality rate of 50% 
[2]. 
Currently, the most important HNC prognostic factor is the presence of regional 
lymph node metastases, which correlates with a 50% reduction in life expectancy [2-4], 
however, micrometastases may not be detected by routine histology [5]. 
Several factors are responsible for the modulation of tumoral growth and patient 
prognosis. Throughout the years, factors that alter proliferation and apoptosis have 
received a lot of attention. It is believed that disequilibrium between proliferation and 
apoptosis may be the key factor in tumor development and prognosis [6]. 
Programmed cell death plays a critical role in the development and homeostasis 
of multicelullar organisms [6]. This complex process involves several genes, as well as 
mutations and polymorphisms that may lead to deficient death signaling and 
potentiation of tumor aggressiveness. Some tumor cells have acquired the ability to 
overcome apoptosis or to induce apoptosis of tumor-specific lymphocytes, favoring 
tumor progression [7]. Apoptosis resistance is a capacity shared by most malignancies. 
Subversion of apoptotic pathways is a major mechanism in cancer devopment, being 
also related with tumor aggressiveness, histological differentiation and prognosis [8,9]. 
FAS (CD95), a member of the TNF family, is a transmembrane protein with 
cystein rich extracellular domains and a death cytoplasmatic domain, common to all 
family members and essential in the translation of the death stimulus [10,11]. 
Immediately after the receptor stimulation by the FASL ligand (CD95L), the apoptotic 
signal is transmitted through the adapter FADD (FAS Associated Death Domain), which 
converts caspase 8 zymogen into its active form, triggering the apoptosis start. 
Activation of this cascade will culminate into DNA fragmentation, causing radical 
morphological and biochemical intracellular changes [11-12]. 
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FAS/FASL altered expression may cause tumor protecting immunomodulation, 
with a direct impact on patient prognosis [13]. In a previous study, microarray 
experiments compared gene expression between more aggressive oral tumors (tumors 
with premature metastasis; T1/T2, N+) and more benign tumors (advanced tumors 
without metastasis; T3/T4, N0). These results generated a list of genes with differential 
expression, where FAS and FASL were among the least expressed in more benign 
tumors, suggesting a role in tumor apoptosis resistance [14]. Owing to these results, the 
present study aimed to correlate FAS/FASL tumor expression with clinical variables, 
tumor histology and prognosis of squamous cell carcinoma of the oral cavity. 
 
MATERIALS AND METHODS 
Ethics 
This study was approved by the Research Ethics Committee of the Heliopolis 
Hospital on 08/12/2008 (CEP no 637) and an informed consent was obtained from all 
patients enrolled. 
 
Samples 
Samples were collected by the Head and Neck Genome Project (GENCAPO), a 
collaborative consortium created in 2002 with more than 50 researchers from 9 
institutions in São Paulo State, Brazil, whose aim is to develop clinical, genetic and 
epidemiological analysis of HNSCC. In this study, 60 tumoral tissue samples were 
obtained and used for immunohistochemical analysis of the FAS and FASL gene, 
within a total of 60 patients with oral squamous cell carcinomas, surgically treated at the 
Head and Neck Surgery Department of Heliópolis Hospital, São Paulo, Brazil, during 
the period of January/2002 to December/2008. The clinical follow-up was at least 48 
months after surgery. Previous surgical or chemotherapic treatment, distant metastasis, 
no removal of cervical lymph nodes and positive surgical margins were exclusion 
criteria. Histopathological slides were reviewed by a senior pathologist to confirm the 
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diagnosis and select appropriate areas for immunohistochemical analysis. Tumors were 
classified according to the TNM system (3
rd
 edition) [15]. Clinical, epidemiological and 
pathological tumor characteristics are described in Table 1 and 2. 
 
Tissue microarray 
Formalin-fixed, paraffin-embedded tissue sections of 60 primary oral squamous 
cell carcinomas treated at the Head and Neck Surgery Department of Heliópolis 
Hospital, São Paulo, Brazil, were used for immunohistochemistry (IHC) analysis. 
Histological characterization of all samples was done by hematoxylin and eosin 
staining, followed by immunohistochemistry analysis of tissue microarrays (TMA). 
Two 1mm cylinders were used to represent each sample in the TMA slide (Beecher 
Instruments
®
, Silver Spring, MD, USA). 
 
Immunohistochemistry 
Anti-FAS monoclonal antibody and anti-FASL monoclonal antibody (Santa 
Cruz Biotechnology
®
, USA) were used in the IHC reaction, at a 1:400 dilution [16-18]. 
Positive and negative controls were used. Sample scoring was performed by semi-
quantitative microscopic analysis, considering the number of stained cells and signal 
intensity. Two spots were evaluated for each sample and a mean score was calculated. 
Considering the percentage of immune-positive tumor cells, a score of 1 was given 
when ≤10% of cells were positive; 2 when 10-50% of cells were positive and 3 when 
≥50% of cells were positive. Signal intensity was scored as negative (0), weak (1), 
moderate (2) and strong (3). Both scores were multiplied [19,20] and the resulting score 
was used to categorize FAS and FASL expression as positive (>3, Figure 1a and 1b, 
respectively) and negative (≤3, Figure 1c). 
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Statistical Analysis 
The chi square and Fisher exact tests were used for association analysis and 
confirmation was obtained by the Lilliefors test (significance considered when p<0.05). 
Multivariate logistic regression was used to obtain odds ratio (OR) and confidence 
intervals (CI 95%). Survival was calculated by the number of months between surgery 
and death for each patient or the last appointment in case the patient was alive. In order 
to calculate disease-free survival, the time endpoint was the date of disease relapse. The 
Kaplan-Meier model was used for survival analysis, using the Wilcoxon p-value and the 
Cox Proportional Hazards to adjust p-values and obtain hazard ratio (HR). Statistical 
calculations were performed using the Epi Info
®
 v3.4.3, 2007 and Statsoft Statistica
®
 
v7.0.61.0 softwares. 
 
RESULTS 
FAS expression 
FAS expression was studied in 60 tumors, of which 28 were positive (46.7%) 
and 32 were negative (53.3%). FAS expression did not show a significant association 
with tumor characteristics such as size (p=0.233) and differentiation grade (p=0.441), 
but was significantly associated with positive lymph nodes (p=0.004, Table 2). 
Multivariate analysis showed that negative FAS expression was an independent marker 
for lymph node positivity (OR=5.02, CI=1.34-18.75, Table 3). 
FAS expression was significantly associated with disease specific death 
(p<0.001, Table 2) and multivariate analysis showed that negative expression was an 
independent death risk factor, increasing risk 4 times when compared to positive 
expression (OR=4.59, CI=1.01-21.51, Table 3). Nonetheless, FAS expression was not 
correlated with disease relapse (p=0.080, Table 2). 
Disease-free and disease-specific survival were significantly correlated with 
FAS expression (p=0.025 and p<0.001, respectively). According to a 24 month after 
surgery follow up, approximately 70% of cases with negative expression presented 
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disease relapse, as compared to approximately 25% of recurrence in patients with 
positive expression of FAS (Figure 2a). Additionally, according to a 36 month after 
surgery follow up, approximately 65% of cases with negative expression died of disease 
specific causes, as compared to 15% of deaths in patients with positive expression of 
FAS (Figure 2b). Multivariate analysis revealed that a negative expression of FAS was 
an independent marker for earlier disease specific death, showing a 3-fold increased risk 
when compared to positive expression (HR=3.73, CI=1.16-11.95, Table 3), but the same 
association was not found for disease relapse (HR=1.66, CI=0.69-3.97, Table 3). 
 
FASL expression 
Regarding FASL, 33 (55.0%) tumors showed positive expression, whereas 27 
(45.0%) were negative. FASL expression was significantly associated with 
differentiation grade (p=0.003), but was not associated with tumor size (p=0.297) or 
positive lymph nodes (p=0.548, Table 2). 
FASL expression did significantly correlate with disease relapse (p=0.007) and 
disease specific death (p=0.006, Table 2). Multivariate analysis showed that negative 
FASL was an independent marker of disease relapse and disease specific death, 
representing an increased risk of over 6 times for each, when compared to a positive 
expression (respectively, OR=5.51, CI=1.32-23.04 and OR=6.06, CI=1.05-35.06; Table 
3). 
In contrast, disease-free and disease-specific survival were not associated with 
FASL expression (p=0.143 and p=0.097, respectively, Figure 2c and 2d). 
 
FAS/FASL Profiles 
In an attempt to combine FAS and FASL expression results, we categorized the 
FAS/FASL profile in three classes: low risk (positive FAS and FASL expression); 
intermediate risk (negative expression of one marker) and high risk (negative expression 
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of both markers). Frequencies of each FAS/FASL profiles were 20 (33.3%), 21 (35.0%) 
and 19 (31.7%), respectively for low, intermediate and high risk. 
Disease-free and disease-specific survival were significantly correlated with 
FAS/FASL profiles (p=0.038 and p=0.008, respectively). On a 24 month after surgery 
follow up, 80% of cases classified as high risk had relapsed and approximately 70% 
died of disease-specific causes, compared to approximately 30% of relapse and 15% of 
death in patients classified as low risk (Figure 3a and 3b). Multivariate analysis revealed 
that the high risk category is an independent marker for earlier disease relapse and 
disease-specific death, with approximately 4- and 6-fold increased risk, respectively, 
when compared to the low risk profile (HR=3.80, CI=1.19-12.52 and HR=6.43, 
CI=1.45-28.55). 
 
DISCUSSION AND CONCLUSIONS 
Apoptosis is a physiological process of cell number control, which plays an 
important role in cellular homeostasis and embryonic development [21-24]. Cell 
population is defined by a balance between proliferation and survival and disruption of 
this balance can lead to cancer growth [25-32]. 
The extrinsic apoptosis pathway can be triggered by enzymes of the TNF family, 
including FAS and FASL. FASL positive T-cells can eliminate FAS positive tumoral 
cells by inducing apoptosis [10,12]. Therefore, reduction or loss of FAS expression may 
result in decreased sensitivity of tumoral cells to cytotoxic activity, impairing apoptosis. 
FAS expression has been previously associated with tumor apoptosis in the 
stomach [13], esophagus [33] and liver [34]. In addition, FAS/FASL diminished 
expression correlates with worse prognosis in lung [35] esophageal [36], larynx [37], 
colorectal [38] and gastric [39] tumors. 
In agreement with the literature, our results show that negative FAS expression 
correlates with lymph node metastasis (5 times increased risk). When compared with 
positive expression, negative expression was significantly associated with cancer related 
129 
 
deaths and shorter disease-free and disease-specific survival. Multivariate analysis 
confirmed that negative FAS expression was an independent risk factor for death and 
disease-specific survival reduction, increasing risk approximately 5 times for each. Our 
results also showed that negative FASL expression was associated with increased 
disease relapse and disease-related deaths. Multivariate analysis confirmed that FASL 
negative expression was an independent risk factor for disease relapse and death, 
increasing risk up to 6 times when compared to positive expression. However, FASL 
expression was not related to worse disease-free survival or disease-specific survival. 
In contrast with our results, other studies have revealed higher FASL expression 
as a marker of worse prognosis in esophageal [36] and lung [40-42] tumors. Their 
hypothesis relies on tumor FASL expression as a T-cell apoptosis inducer, resulting in 
lower tumor attack by the immune system [43-45]. However, our results support the 
hypothesis that the immune system response is already compromised in oral cancer, 
most likely because it is a tobacco/alcohol associated disease[46]. As previously 
reported, chronic alcohol consumption impairs Natural Killer cell (NK) activity and 
decreases NK cell number, therefore affecting their ability to destroy tumor cells [47]. 
In addition, several studies have reported a similar decrease in number and activity of 
NK cells in smokers [48,49], in which cases a lower production of interferon-c and 
TNF-a cytokines is observed [50]. Based on these facts, our hypothesis predicts that the 
oral immune response is attenuated in patients with chronic tobacco and alcohol 
consumption, therefore in these individuals, a lack of FASL may represent a loss of the 
extrinsic apoptosis signal in tumor cells, conferring a worse prognosis. 
In summary, our results correlate a negative FAS/FASL expression with worse 
prognosis in oral squamous cell carcinoma patients, suggesting that these proteins play 
important roles in oral cancer cell apoptosis. 
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FIGURE LEGENDS 
Figure 1. Immunohistochemical. a. Positive FAS expression; b. Positive FASL 
expression; c. Negative immunostaining. Magnification was 400x. 
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Figure 2. Survival plots. a. and b.: Disease-free survival and disease-specific survival 
according to FAS expression; c. and d.: Disease-free survival and disease-specific 
survival according to FASL expression. 
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Figure 3. Survival plots. a. and b.: Disease-free survival and disease-specific survival 
according to FAS/FASL profile. 
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TABLES 
 
Table 1. Epidemiological features. 
Epidemiological features 
Total 
No. (%) 
   
Gender   
Female 8 (13.3) 
Male 52 (86.7) 
Age, yr   
Median 55, df ±10.7   
Tobacco and Alcohol habits   
Smoker and alcoholic 50 (83.3) 
Only smoker 7 (11.7) 
Only alcoholic 1 (1.7) 
Tumor sub-sities   
Tongue 22 (36.7) 
Gum 12 (20.0) 
Floor mouth 21 (35.0) 
Retromolar area 5 (8.3) 
Treatment   
Only operated 60 (100.0) 
Operated + irradiated 31 (51.7) 
Total 60 (100.0) 
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Table 2. Epidemiological, clinical and pathological tumor features and their association 
with FAS and FASL expression. 
Clinical and 
pathological features 
Total 
 FAS expression  FASL expression 
 Negative Positive 
p 
 Negative Positive 
p 
No. (%)  No. No.  No. No. 
           
Stage           
2 17 (28.3)  6 11 0.025  7 10 0.177 
3 17 (28.3)  7 10   5 12  
4 26 (43.4)  19 7   15 11  
Tumor size (T)
 ¥
           
T1+T2 24 (40.0)  11 13 0.233  8 16 0.297 
T3 12 (20.0)  5 7   7 5  
T4 24 (40.0)  16 8   12 12  
Lymph nodes (N)
 ¥
           
Absent 27 (45.0)  9 18 0.004  11 16 0.548 
Present 33 (55.0)  23 10   16 17  
Diferentiation           
Well 26 (43.4)  16 10 0.441  18 8 0.003 
Moderately 29 (48.3)  13 16   7 22  
Poorly 5 (8.3)  3 2   2 3  
Disease specific death           
No 32 (53.3)  11 21 < 0.001  9 23 0.006 
Yes 25 (41.7)  20 5   16 9  
Not available* 3 (5.0)       1  
Disease relapse           
No 26 (43.4)  10 16 0.080  6 20 0.007 
Yes 29 (48.3)  18 11   17 12  
Not available* 5 (8.3)         
Total 60 (100.0)  32 28   27 33  
¥
 TNM classification 3
rd
 edition 
* Not available (not considered in the statistical calculations). 
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Table 3. Multivariate analysis of the relationship between clinical, pathological tumor features and survival with FAS and FASL expression. 
Variables 
Logistic regression  Cox proportional hazard 
Lymph-nodes  Disease relapse  Disease specific death  Disease-free survival  Disease-specific survival 
OR (95% CI)
¥
 p
¥
  OR (95% CI)
¥
 p
¥
  OR (95% CI)
¥
 p
¥
  HR (95% CI)
§
 p
§
  HR (95% CI)
§
 p
§
 
               
FAS expression               
Positive 1   1   1   1   1  
Negative 5.02 (1.34-18.75) 0.017  1.49 (0.39-5.78) 0.561  4.59 (1.01-21.51) 0.050  1.66 (0.69-3.97) 0.257  3.73 (1.16-11.95) 0.027 
FASL expression               
Positive 1   1   1   1   1  
Negative 1.22 (0.30-5.00) 0.780  5.51 (1.32-23.04) 0.019  6.06 (1.05-35.06) 0.044  2.58 (1.03-6.46) 0.044  2.14 (0.73-6.30) 0.166 
Tumor size (T)               
T1+T2 1   1   1   1   1  
T3 1.62 (0.30-8.67) 0.576  1.63 (0.29-9.25) 0.581  2.32 (0.33-16.20) 0.395  2.31 (0.73-7.35) 0.156  3.00 (0.76-11.91) 0.118 
T4 4.44 (1.08-18.20) 0.038  2.68 (0.62-11.55) 0.186  2.76 (0.51-14.84) 0.236  2.05 (0.77-5.50) 0.152  1.97 (0.63-6.22) 0.245 
Differentiation               
Well 1   1   1   1   1  
Moderately 3.56 (0.81-15.63) 0.092  1.09 (0.24-4.96) 0.909  1.66 (0.26-10.44) 0.589  1.57 (0.57-4.35) 0.385  1.84 (0.56-6.05) 0.318 
Poorly 6.07 (0.45-81.73) 0.174  0.28 (0.03-2.97) 0.291  7.19 (0.37-139.86) 0.193  0.54 (0.11-2.79) 0.465  1.94 (0.41-9.17) 0.405 
Lymph-nodes               
Absent ─ ─  1   1   1   1  
Present ─ ─  4.07 (0.48-34.40) 0.197  13.55 (0.94-195.73) 0.056  2.28 (0.62-8.33) 0.214  3.49 (0.78-15.65) 0.102 
Irradiated               
No ─ ─  1   1   1   1  
Yes ─ ─  0.17 (0.02-1.27) 0.085  0.30 (0.02-3.68) 0.344  0.30 (0.09-0.97) 0.044  0.52 (0.17-1.56) 0.241 
OR – Odds ratio; HR – Hazard ratio; CI – Confidence interval 
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¥
 Values adjusted by multivariate logistic regression. 
§
 Values adjusted by Cox proportional hazards. 
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4.5. Manuscrito 1: LEPR expression and Gln223Arg polymorphism as a 
prognostic marker in squamous cell carcinoma of the oral cavity and oropharynx 
 
O manuscrito intitulado “LEPR expression and Gln223Arg polymorphism as a 
prognostic marker in squamous cell carcinoma of the oral cavity and oropharynx” foi 
submetido para a revista Molecular Biology Reports, a qual possui fator de impacto de 
2.506 (JCR 2012). 
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LEPR EXPRESSION AND GLN223ARG POLYMORPHISM AS A 
PROGNOSTIC MARKER IN SQUAMOUS CELL CARCINOMA OF THE 
ORAL CAVITY AND OROPHARYNX 
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ABSTRACT 
The Leptin gene product is released into the blood stream, passes through the blood-
brain barrier and finds its receptor (LEPR) in the central nervous system. This hormone 
regulates food intake, hematopoiesis, inflammation, immunity, differentiation and cell 
proliferation. The LEPR Gln223Arg polymorphism has been reported to alter receptor 
function and expression. They have both been related with prognostic in several tumor 
types. Furthermore, several studies have shown a relationship between the Glin223Arg 
polymorphism and tumor development. Nonetheless, its role in oral and oropharyngeal 
squamous cell carcinoma is now well understood. In this study, 315 DNA samples were 
used for LEPR Gln223Arg genotyping and 87 primary oral and oropharyngeal 
squamous cell carcinomas were used for immunohistochemistry (IHC) analysis, such 
that a relationship between these and tumor development and prognosis could be 
established. Homozygous LEPR Arg223 was related with a reduction in oral and 
oropharyngeal cancer risk by 2 fold. In contrast, presence of the Arg223 allele in tumors 
was associated with worse disease-free and disease-specific survival. Low LEPR 
expression was an independent risk factor, increasing 4 times the risk for lymph node 
metastasis. In conclusion, the Gln223Arg polymorphism and LEPR expression may be 
valuable markers for oral and oropharyngeal cancer, suggesting LEPR as a potential 
target for future therapies. 
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INTRODUCTION 
Head and neck cancer (HNC) is a significant cause of mortality and morbidity 
worldwide, presenting approximately 600,000 new cases yearly [1], whereas tumors of 
the oral cavity contribute with 389,000 new cases per year, with a mortality rate of 50% 
[2,3]. HNC has a multifactor etiology involving smoking and drinking habits, HPV 
(Human Pappillomavirus) infection and genetic factors [4]. 
Leptin is a hormone released into the blood stream and transfered through the 
blood-brain barrier, reaching its receptor LEPR (also known as OBR) located at the 
plasma membrane of hipothalamus cells. This hormone regulates food intake, 
hematopoiesis, inflammation, immunity, cell differentiation and proliferation [5-7]. 
LEPR is a member of a family of citokine class 1 receptors [8]. Upon ligand 
binding, LEPR undergoes structural changes, which tethers Janus Kinase (JAK) 
molecules, enabling cross phosporilation. This step is needed for phosphorilation of 
Signal Transducer and Activator of Transcription (STAT) molecules at the cytoplasmic 
region of the receptor. STAT3 autodimerizes after phosphorilation of JAK2 and 
translocates into the nucleus, where it is going to activate transcription at specific gene 
promoters. Among the various genes induced by STAT3, there are enzymes involved in 
the development of many tumors [6,9-11]. 
Several LEPR polymorphisms have been described in humans. An A/G transition 
at nucleotide 668 converts a glutamine to an arginine at codon 223 (Gln223Arg) of this 
protein. This transition results in an exchange of a neutral aminoacid for one with a 
positive charge, altering receptor function and signalling capacity, modifying circulating 
lepting levels [10]. This polymorphism is located inside the extracellular domain coding 
region, affecting the entire structure of the receptor [12]. 
Previous studies have correlated the Gln223Arg polymorphism and LEPR 
expression with develpment and prognosis of several tumors, such as breast, [10,13-15], 
lung [12], stomach [16] and prostate [17]. However, conclusive data is not yet available 
for HNC and studies are scarce. Therefore, the present study aimed to analyse 
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Gln223Arg polymorphism and LEPR expression with develpment, prognosis and 
survival of patients with oral and oropharyngeal cancer. 
 
MATERIALS AND METHODS 
Ethics 
This study was approved by the Committee of Ethics in Research of the 
Heliopolis Hospital (CEP # 446) and an informed consent was obtained from all 
patients enrolled. 
 
Samples 
Samples were collected by the Head and Neck Genome Project (GENCAPO), a 
collaborative consortium created in 2002 with more than 50 researchers from 
institutions in Brazil. In this study, 315 DNA samples obtained and used for 
polymorphism LEPR Gln223Arg genotyping, being 186 (59.0%) individuals controls 
had no history of cancer and 129 (41.0%) patients with oral and oropharyngeal 
squamous cell carcinomas. The LEPR immunohistochemical analysis was performed on 
tumoral tissue samples of 87 patients with oral and oropharyngeal squamous cell 
carcinomas, surgically treated at the Head and Neck Surgery Department of Heliópolis 
Hospital and Arnaldo Vieira de Carvalho Câncer Hospital, São Paulo, Brazil, during the 
period of January/2002 to December/2009. The clinical follow-up was at least 48 
months after surgery. Previous surgical or chemotherapic treatment, distant metastasis, 
no removal of cervical lymph nodes and positive surgical margins were exclusion 
criteria [18]. 
Among analyzed individuals, mean age was 54.2 years (df ±11.1), being 173 
(93.0%) men and 13 (7.0%) women in the control group. For patients with head and 
neck cancer, mean age was 54.9 years (df ±10.7), being 110 (85.3%) men and 25 
(19.4%) women (Table 1). According to the anatomical localization of the tumor, 95 
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(73.6%) were on the oral cavity and 34 (26.4%) on the oropharynx. Clinical-
pathological characteristics of tumors are described in Table 2. 
 
Genotyping 
Genomic DNA was extracted from peripheral blood samples of 315 individuals 
(cancer patients and controls) as previously described [19]. Genotypes were determined 
by polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). 
LEPR exon 6 was amplified using primers described by Snoussi et al. and analyzed for 
Gln223Arg polimorphism (rs1137101) [5]. Selected primers were 5’ – AAA CTC AAC 
GAC ACT CTC CTT – 3’ and 5’ – TGA ACT GAC ATT AGA GGT GAC –3’, which 
produce an 80-base pair (bp) fragment. PCR conditions were: a 25L reaction mixture 
containing 200ng of genomic DNA, 10mM Tris-HCl (pH 8.3), 50mM KCl, 200M of 
each deoxyribonucleoside 5´ triphosphates, 1.5mM de MgCl2, 1U Taq DNA polimerase 
(Life Technologies Inc
® 
, Rockville, MD, USA) and 25pmol of each primer (Biobrás
® 
, 
São Paulo, SP, Brasil). PCR initiated with a melting step of 5 minutes at 94C, followed 
by 35 cycles of 30 seconds at 94C, 45 seconds at 52°C and 45 seconds at 72C and 5 
minutes extension at 72ºC. PCR products were digested overnight with MspI (New 
England Biolabs
® , Berverly, MA, USA) following the manufacturer’s instructions. 
Restriction fragments were resolved on a 12% non-denaturing polyacrylamide gel. SNP 
Arg223 in LEPR gene was characterized by two distinctive fragments of 58 and 22-bp, 
whereas the LEPR Gln223 wild-type allele was identified by a single fragments of 80-
bp. 
 
Tissue microarray 
Tissue microarrays were made using buffered formalin-fixed paraffin-embedded 
tissue sections from 87 primary oral and oropharyngeal squamous cell carcinomas 
treated at the Head and Neck Surgery Department of Heliópolis Hospital, São Paulo, 
SP, were used for immunohistochemistry (IHC) analysis. Histological characterization 
of all samples was done by Hematoxylin and Eosin staining, followed by 
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immunohistochemistry analysis of tissue microarrays (TMA). Two 1mm cylinders were 
used to represent each sample in the TMA slide (Beecher Instruments
® 
, Silver Spring, 
MD, USA). 
 
Immunohistochemistry 
Anti-LEPR policlonal antibody (Santa Cruz Biotechnology
® 
, USA) was used in 
the IHC reaction, at a 1:50 dilution [20-22]. Positive and negative controls (absence of 
primary antibody) were used for reaction quality control. Sample scoring was performed 
by semi-quantitative microscopic analysis, considering the number of stained tumor 
cells and signal intensity. Two spots were evaluated for each sample and a mean score 
was calculated. Considering the percentage of LEPR immune-positive tumor cells, a 
score of 1 was given when ≤10% of cells were positive; 2 when 10-50% of cells were 
positive and 3 when ≥50% of cells were positive. Signal intensity was scored as weak 
(1), moderate (2) and strong (3). Both scores were multiplied [23,24] and the resulting 
score was used to categorize LEPR expression as low (<4) and high (≥4). 
 
Statistical Analysis 
The chi square and Fisher exact tests were used for association analysis and 
confirmation was obtained by the Lilliefors test (significance considered when p<0.05). 
Multivariate logistic regression was used to obtain odds ratio (OR) and confidence 
intervals (CI≥ 95%). Survival was calculated by the number of months between surgery 
and death for each patient or the last appointment in case the patient was alive. In order 
to calculate disease-free survival, the time endpoint was the date of disease relapse. The 
Kaplan-Meier model was used for survival analysis, using the Wilcoxon p-value and the 
Cox Proportional Hazards to adjust p-values and obtain hazard ratio (HR). Statistical 
calculations were performed using the Epi Info
® 
 v3.4.3, 2007 and Statsoft Statistica
®  
v7.0.61.0 softwares. 
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RESULTS 
LEPR Gln223Arg Polymorphism 
Regarding the LEPR Gln223Arg polymorphism frequencies, 60 (46.5%) patients 
with cancer were genotyped as wild type allele Gln/Gln, 61 (47.3%) as Gln/Arg and 8 
(6.2%) as Arg/Arg. In the  control group, 68 (36.5%) individuals were genotyped as 
Gln/Gln, 92 (49.5%) as Gln/Arg and 26 (14.0%) as Arg/Arg. The observed genotype 
frequencies of LEPR Gln223Arg polymorphism were at Hardy-Weinberg equilibrium in 
the controls (p=0.563). The Arg223 allele in homozygosis was more frequent in control 
individuals than in cases, with a significant association (p=0.045). Multivariate analysis 
showed that Arg/Arg genotype is an independent factor for head and neck cancer 
development, representing a decreased risk of approximately 2.5 times in relation to the 
wild-type genotype (Gln/Gln) (OR=0.40, CI=0.16-0.97, Table 1). However, the 
genotype Gln/Arg showed no relation to risk. 
The Gln223Arg polymorphism did not show a significant association with tumor 
size (p=0.406), lymph node metastases (p=0.430), lymphatic invasion (p=0.824) and 
perineural invasion (p=0.621), but was significantly associated with differentiation 
grade (p=0.038, Table 2). It was also significantly associated with disease relapse 
(p=0.003) and disease specific death (p=0.039, Table 2). Multivariate analysis showed 
that presence of Arg223 allele was an independent marker of disease relapse 
representing an increased risk of over 3 times, when compared to the absence of this 
allele (OR=3.30, CI=1.37-7.93), but the same association was not found for disease 
specific death (OR=2.40, CI=0.95-6.08; Table 3). 
Disease-free and disease specific survival were significantly correlated with 
Gln223Arg polymorphism (p=0.001 and p=0.012, respectively). According to a 24 
month after surgery follow up, approximately 60% of cases with at least one Arg223 
allele presented disease relapse, as compared to approximately 30% of recurrence in 
patients without the Arg223 allele (Figure 1a). Additionally, according to a 36 month 
after surgery follow up, approximately 60% of cases with at least one Arg223 allele 
died of disease specific causes, as compared to approximately 20% of deaths in patients 
without the Arg223 allele (Figure 1b). Multivariate analysis revealed that presence of 
152 
 
Arg223 allele in LEPR gene is an independent marker for early disease relapse and 
disease specific death, with a 2-fold increased risk when compared to absence of this 
allele (respectively, HR=2.38, CI=1.29-4.29 and HR=2.11, CI=1.05-4.24, Table 4). 
 
LEPR Expression 
LEPR expression was evaluated in 87 tumors, being classified as low in 40 
(46.0%) and high in 47 (54.0%). LEPR expression did not show a significant 
association with tumor characteristics such as size (p=0.844), differentiation grade 
(p=0.761), lymphatic invasion (p=0.604) and perineural invasion (p=0.054), but was 
significantly associated with lymph nodes metastases (p=0.006, Table 2). Multivariate 
analysis showed that low LEPR expression is an independent marker for lymph nodes 
metastases (OR=3.75, CI=1.40-10.04, Table 3). 
In contrast, the LEPR expression did not significantly correlate with disease 
relapse (p=0.149) and disease specific death (p=0.123, Table 2), as well as disease-free 
and disease-specific survival (p=0.407 and p=0.259, respectively, Figure 1c and 1d). 
 
DISCUSSION AND CONCLUSIONS 
Leptin is a cell growth factor hormone that has been related with tumor cell 
migration and invasion, as well as angiogenesis in some tumors [25]. LEPR is involved 
with several signalling pathways, such as JAK/STAT, Phosphatidilinositol 3-kinase 
(PI3K), Protein Kinase B (AKT) and Mitogen Activated  Protein Kinase (MAPK). 
These pathways, under leptin-LEPR control, are strongly related with cell survival and 
differentiation [26]. 
The aminoacid exchange caused by the LEPR Gln223Arg gene polymorphism 
yields a weaker interaction between leptin and its receptor, and as a result of that, a 
reduction in cell growth signalling [27]. Our results show that Arg223 homozygous 
genotype was related with a 2,5 smaller risk of delevoping cancer, when compared to 
the Gln223 homozygous variant. Similar results were reported in prostate cancer, 
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suggesting that this allele increases tumor development risk [28]. Therefore, Gln223Arg 
may play an important role in the inhibition of cell division [29]. In contrast, in breast 
cancer, it appears that the Arg223 allele increases cancer risk [5], shedding uncertainty 
as to through which mechanism this allele interacts with oncogenesis. 
In contrast, our results suggest that presence of Arg223 is related with relapse 
risk and with worse disease-free and disease-specific survival. Similar studies in breast 
[5] and prostate cancer [28], show that Arg223 bearing patients have a significant 
increased risk of relapse, and consequently worse prognosis. Reports that high levels of 
circulating leptin are related with a decreased globa survival of breast cancer patients 
[30] and that a weak interaction between Leptin-LEPR favours angionesis and tumor 
growth [31,32], support the hypothesis that presence of Arg223 may result in worse 
prognosis in these patients. In contrast with these results, lung [12] and colorectal 
cancer [11] studies present allele Gln223 as the one related with worse prognosis. 
According to our results, low LEPR expression increasis the risk of lymph node 
metastasis by 4 fold, when compared with strong expression. Considering that weak 
LEPR expression has a similar effect to the Gln223Arg polymorphism, weak Leptin-
LEPR interaction and increased circulating Leptin, [31,33], these effects have been 
previously suggested as facilitators of tumor invasion and metastasis [11,34]. 
In conclusion, the present work attributed a protective role to the homozygous 
LEPR Arg223 allele in oral and oropharyngeal cancer. Arg223 showed to be an 
independent marker of worse prognosis, as shown by a lower disease-free and disease-
specific survival. Low LEPR expression was an independent marker of metastasis risk, 
showing a 4-fold increased risk of lymph node metastasis. These results suggest a tumor 
marker role for LEPR, as well as a potential target for molecular therapies in oral and 
oropharyngeal cancer patients. 
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FIGURE LEGEND 
Figure 1. Survival plots. a. and b.: Disease-free survival and disease specific survival 
according to LEPR Gln223Arg polymorphism; c. and d.: Disease-free survival and 
disease specific survival according to LEPR expression. 
 
 
  
159 
 
TABLES 
Table 1. Epidemiological features and LEPR Gln223Arg polymorphism associated with 
oral and oropharyngeal cancer risk. 
Features 
Case Control 
P 
Multivariate analysis 
No. (%) No. (%) OR (CI 95%) 
a
 p 
b
 
        
Gender 
       
Female 25 (19.4) 13 (7.0) 0.001 1 
 
Male 110 (85.3) 173 (93.0) 
 
0.12 (0.04-0.35) <0.001 
Age. yr (mean 54.5, df±10.9) 
       
≤ 55 72 (55.8) 105 (56.5) 0.497 ─ ─ 
> 55 63 (48.8) 81 (43.5) 
 
─ ─ 
Smoker 
       
No 59 (45.7) 103 (55.4) 0.039 1 
 
Yes 76 (58.9) 83 (44.6) 
 
3.57 (1.48-8.61) 0.005 
Drinking habit 
       
No 34 (26.4) 96 (51.6) < 0.001 1 
 
Yes 101 (78.3) 90 (48.4) 
 
2.42 (0.98-5.96) 0.055 
LEPR genotype Gln223Arg 
       
Gln/Gln 60 (46.5) 68 (36.5) 0.045 1 
 
Gln/Arg 61 (47.3) 92 (49.5) 
 
0.78 (0.47-1.28) 0.317 
Arg/Arg 8 (6.2) 26 (14.0) 
 
0.40 (0.16-0.97) 0.042 
Total 129 (41.0) 186 (59.0) 
   
OR – Odds ratio; CI – Confidence interval. 
a, b
 Values adjusted by multivariate logistic regression. 
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Table 2. Clinical and pathological tumor features and their association with Gln223Arg 
polymorphism and LEPR expression. 
Features 
LEPR 
Genotype Gln223Arg 
 
Expression level 
Total 
Gln/Gln 
Gln/Arg 
p  
Total 
Low High p 
No. (%) +Arg/Arg 
 
No. (%) 
            
Tumor size (T) 
¥
 
           
T1+T2 50 (38.8) 21 29 0.406 
 
34 (39.1) 15 19 0.844 
T3 31 (24.0) 13 18 
  
21 (24.1) 9 12 
 
T4 48 (37.2) 26 22 
  
32 (36.8) 16 16 
 
Lymph-node (N) 
¥
 
           
Absent (N-) 64 (49.6) 32 32 0.430 
 
33 (37.9) 9 24 0.006 
Present (N+) 65 (50.4) 28 37 
  
54 (62.1) 31 23 
 
Differentiation 
           
Well 52 (40.3) 21 31 0.038 
 
38 (43.7) 18 20 0.761 
Moderately 69 (53.5) 38 31 
  
42 (48.3) 18 24 
 
Poorly 8 (6.2) 1 7 
  
7 (8.0) 4 3 
 
Lymphatic invasion 
           
Negative 61 (47.3) 29 32 0.824 
 
28 (32.2) 14 14 0.604 
Positive 68 (52.7) 31 37 
  
59 (67.8) 26 33 
 
Perineural invasion 
           
Negative 93 (72.1) 42 51 0.621 
 
65 (74.7) 26 39 0.054 
Positive 36 (27.9) 18 18 
  
22 (25.3) 14 8 
 
Disease relapse 
           
No 50 (38.8) 30 20 0.003 
 
35 (40.2) 13 22 0.149 
Yes 52 (40.3) 16 36 
  
45 (51.7) 24 21 
 
Not available * 27 (20.9) 14 13 
  
7 (8.0) 3 4 
 
Disease specific death 
           
No 59 (45.7) 31 28 0.039 
 
42 (48.3) 16 26 0.123 
Yes 41 (31.8) 13 28 
  
36 (41.4) 20 16 
 
Not available * 29 (22.5) 16 13 
  
9 (10.3) 4 5 
 
Total 129 (100.0) 60 69 
  
87 (100.0) 40 47 
 
* Not available(not considered in the statistical calculations). 
¥
 TNM classification 3
rd
 edition. 
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Table 3. Multivariate analysis of the relationship between clinical and pathological tumor features with gene polymorphism and LEPR 
expression. 
Features 
Multivariate Analysis 
Lymph-node (N) 
¥
 
 
Disease relapse 
 
Disease specific death 
OR (95% CI) 
a
 p 
b
 
 
OR (95% CI) 
a
 p 
b
 
 
OR (95% CI) 
a
 p 
b
 
         
LEPR expression 
        
High 1 
  
─ ─ 
 
─ ─ 
Low 3.75 (1.40-10.04) 0.009 
 
─ ─ 
 
─ ─ 
LEPR Gln223Arg 
        
Gln/Gln ─ ─ 
 
1 
  
1 
 
Gln/Arg+Arg/Arg ─ ─ 
 
3.30 (1.37-7.93) 0.008 
 
2.40 (0.95-6.08) 0.065 
Tumor size (T) 
¥
 
        
T1+T2 1 
  
1 
  
1 
 
T3 1.13 (0.36-3.56) 0.833 
 
1.04 (0.34-3.15) 0.946 
 
1.22 (0.37-4.02) 0.740 
T4 4.56 (1.43-14.62) 0.011 
 
1.24 (0.44-3.45) 0.682 
 
2.73 (0.96-7.80) 0.060 
Differentiation 
        
Well 1 
  
─ ─ 
 
─ ─ 
Moderately 2.33 (0.79-6.91) 0.126 
 
─ ─ 
 
─ ─ 
Poorly 3.61 (0.31-42.76) 0.309 
 
─ ─ 
 
─ ─ 
Lymph node (N) 
¥
 
        
Absent (N-) ─ ─ 
 
1 
  
1 
 
Present (N+) ─ ─ 
 
4.67 (1.61-13.59) 0.005 
 
6.67 (2.24-19.87) <0.001 
Irradiated 
        
No ─ ─ 
 
1 
  
1 
 
Yes ─ ─ 
 
0.23 (0.08-0.68) 0.008 
 
0.56 (0.18-1.70) 0.304 
OR – Odds ratio; CI – Confidence interval. 
162 
 
a, b
 Values adjusted by multivariate logistic regression. 
¥
 TNM classification 3
rd
 edition. 
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Table 4. Multivariate analysis of disease specific survival. 
Features 
Cox Proportional 
Disease-free survival 
 
Specific disease survival 
HR (95% CI) 
a
 p 
b
 
 
HR (95% CI) 
a
 p 
b
 
      
LEPR genotype Gln223Arg 
     
Gln/Gln 1 
  
1 
 
Gln/Arg+Arg/Arg 2.38 (1.29-4.39) 0.006 
 
2.11 (1.05-4.24) 0.036 
Tumor size (T) 
¥
 
     
T1+T2 1 
  
1 
 
T3 1.22 (0.58-2.54) 0.598 
 
1.27 (0.52-3.11) 0.604 
T4 1.37 (0.71-2.63) 0.343 
 
1.62 (0.80-3.29) 0.184 
Lymph-node (N) 
¥
 
     
Absent 1 
  
1 
 
Present 2.52 (1.27-4.99) 0.008 
 
3.28 (1.44-7.47) 0.005 
Irradiated 
     
No 1 
  
1 
 
Yes 0.39 (0.20-0.74) 0.004 
 
0.81 (0.37-1.76) 0.592 
HR – Hazard ratio; CI – Confidence interval. 
a, b
 Values adjusted by Cox proportional hazards. 
¥
 TNM classification 3
rd
 edition. 
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4.6. Manuscrito 2: JMJD1A expression as a prognostic marker in squamous 
cell carcinoma of the oral cavity 
 
O manuscrito intitulado “JMJD1A expression as a prognostic marker in 
squamous cell carcinoma of the oral cavity” foi submetido para a revista Plos One, a 
qual possui fator de impacto de 3.73 (JCR 2012). 
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ABSTRACT 
JMJD1A is a histone demethylase, which plays an important role in DNA epigenetic 
regulation, being able to alter gene expression, DNA replication and repair, as well as 
cell differentiation. Moreover, JMJD1A protein has been related with development risk 
and prognosis of several tumor types. Nonetheless, it role in head and neck cancer has 
yet to be clarified. Therefore, we aimed to evaluate JMJD1A expression in 80 
paraffinized oral and oropharyngeal squamous cell carcinoma samples through 
immunohistochemistry analysis. Our results show that nuclear and cytoplasm 
expression were related with risk for lymph node metastasis, in a way that strong 
expression increases risk by 4 to 11 times respectively. In addition, strong expression 
was associated with disease relapse and worse disease specific survival. In conclusion, 
we suggest propose JMJD1A as a promising prognostic marker for oral and 
oropharyngeal squamous cell carcinoma patients. 
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INTRODUCTION 
Head and neck cancer (HNC) is a significant cause of mortality and morbidity 
worldwide, presenting approximately 600,000 new cases yearly [1], whereas tumors of 
the oral cavity (OSCC) contribute with 389,000 new cases per year, with a mortality 
rate of 50% [2,3]. The main prognostic factors for HNC is lymph node metastasis, 
decreasing by 50% the patient survival chance. [4]. 
HNC is a complex disease, caused by multiple factors such as smoking and 
drinking habits, HPV infection, dietary and genetic factors [5]. 
Tumor cell response to hypoxia involves activation of over 100 genes [6]. 
Currently, little is known about the epigenetic relation resulting from HIF system 
transcription activation [7]. However, such changes probably include epigenetic histone 
modifications [8]. 
The protein Jumonji Domain-Containing 1A (JMJD1A, JHDM2A or KDM3A) 
is regulated by HIF1a under hypoxic conditions. JMJD1A gene is activated via its 
hypoxia response elements in the promoter region, promoting demethylation of genes 
that will help cell adaptation in low oxygen environments [9]. Demethylation occurs at 
lysin and arginine residues in an oxygen-dependent reaction that needs Fe (II) ions and 
α-ketoglutarate as cofactors [10]. This can alter tumor cell behavior due to chromatin 
structural changes, gene expression and DNA repair [8,11]. 
In embryonic stem cells, JMJD1A helps maintain pluripotency, inhibiting 
demethylation of differentiation gene promoters [12]. JMJD1A has been associated with 
development and prognosis of several tumor types, such as colorectal [13], 
nasopharyngeal [14], hepatocellular [15] and renal [16] tumors. Its role in HNC is still a 
matter of debate. 
Therefore, we have aimed to study the association of JMJD1A with 
clinicopathological features and prognosis of patients with HNC or the oral and 
oropharyngeal cavities. 
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MATERIALS AND METHODS 
Ethics 
This study was approved by the Committee of Ethics in Research of the 
Heliópolis Hospital (CEP # 619) and a written informed consent was obtained from all 
patients enrolled. 
 
Samples 
Samples were collected by the Head and Neck Genome Project (GENCAPO), a 
collaborative consortium created in 2002 with more than 50 researchers from 9 
institutions in São Paulo State, Brazil, whose aim is to develop clinical, genetic and 
epidemiological analysis of HNSCC. In this study, 80 tumoral tissue samples were 
obtained and used for immunohistochemical analysis of the JMJD1A, within a total of 
80 patients with oral and oropharyngeal squamous cell carcinomas, surgically treated at 
the Head and Neck Surgery Department of Heliópolis Hospital, São Paulo, Brazil, 
during the period of January/2002 to December/2008. The clinical follow-up was at 
least 24 months after surgery. Previous surgical or chemotherapic treatment, distant 
metastasis, no removal of cervical lymph nodes and positive surgical margins were 
exclusion criteria. Histopathological slides were reviewed by a senior pathologist to 
confirm the diagnosis and select appropriate areas for immunohistochemical analysis. 
Tumors were classified according to the TNM system (3
rd
 edition) [17]. 
Among the analyzed individuals, the mean age was 54.4 years (df ±10.4) being 
68 (85%) men and 12 (15%) women. According to tumor anatomical sites, 60 (75%) 
were in the oral and 20 (25%) in the oropharyngeal cavity (Table 1). 
 
Tissue microarray 
Tissue microarrays were made using buffered formalin-fixed paraffin-embedded 
tissue sections from 80 primary oral and oropharyngeal squamous cell carcinomas 
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treated at the Head and Neck Surgery Department of Heliópolis Hospital, São Paulo, 
SP, were used for immunohistochemistry (IHC) analysis. Histological characterization 
of all samples was done by Hematoxylin and Eosin staining, followed by 
immunohistochemistry analysis of tissue microarrays (TMA). Two 1mm cylinders were 
used to represent each sample in the TMA slide (Beecher Instruments
®
, Silver Spring, 
MD, USA).  
 
Immunohistochemistry 
Anti-JMJD1A monoclonal antibody (Abcam
®
) was used in the IHC reaction, at 
a 1:400 dilution [18-20]. Positive and negative controls (absence of primary antibody) 
were used for reaction quality control. Sample scoring was performed by semi-
quantitative microscopic analysis, considering the number of stained tumor cells and 
signal intensity. Two spots were evaluated for each sample and a mean score was 
calculated. Considering the percentage of JMJD1A immune-positive tumor cells, a 
score of 1 was given when ≤10% of cells were positive; 2 when 11-50% of cells were 
positive and 3 when >50% of cells were positive. Signal intensity was scored as 
negative (0), weak (1), moderate (2) and strong (3). Both scores were multiplied [21,22] 
and the resulting score was used to categorize JMJD1A expression as negative (0), 
positive low (1-4) and positive high (≥4). 
 
Statistical Analysis 
The chi square and Fisher exact tests were used for association analysis and 
confirmation was obtained by the Lilliefors test (significance considered when p<0.05). 
Multivariate logistic regression was used to obtain odds ratio (OR) and confidence 
intervals (CI ≥95%). Survival was calculated by the number of months between surgery 
and death for each patient or the last appointment in case the patient was alive. In order 
to calculate disease-free survival, the time endpoint was the date of disease relapse. The 
Kaplan-Meier model was used for survival analysis, using the Wilcoxon p-value and the 
Cox Proportional Hazards to adjust p-values and obtain hazard ratio (HR). Statistical 
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calculations were performed using the Epi Info
®
 v3.4.3, 2007 and Statsoft Statistica
®
 
v7.0.61.0 softwares.
 
 
RESULTS 
JMJD1A nuclear expression positivity was studied in 80 tumors, of which 27 
were negative (33.8%), 31 were weakly positive (38.8%) and 22 were strongly positive 
(27.5%). Regarding JMJD1A cytoplasmic expression, 11 were negative (13.8%), 63 
(78.8%) were weakly positive and only 6 (7.5%) were strongly positive. Differential 
expression by intracellular localization was significantly different (p <0.001, Table 2). 
 
JMJD1A cytoplasmic expression 
Positive JMJD1A cytoplasmic expression did not show a significant association 
with differentiation grade (p=0.342), disease relapse (p=0.414) and disease specific 
death (p=0.434), but the expression was significantly associated with tumor size 
(p=0.023) and lymph-node status (p<0.001, Table 3). Multivariate analysis showed that 
positive JMJD1A cytoplasmic expression was an independent marker for lymph-node 
positivity, yielding an approximately 11-fold increased risk (OR=11.46, CI=1.10-
119.38, Table 4). In addition, cytoplasmic expression levels did not show a significant 
relation with tumor characteristics such as size (p=0.432), differentiation grade 
(p=0.590), lymph node status (p=0.341), disease relapse (p=0.081) and disease specific 
death (p=0.178, Table 4). 
Cytoplasmic expression positivity was not significantly associated with disease 
free and disease specific survival (p=0.505 and p=0.670, respectively), neither was 
expression levels (p=0.150 and p=0.159, respectively; data not show). 
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JMJD1A nuclear expression 
Positive JMJD1A nuclear expression did not show a significant association with 
tumor characteristics such as size (p=0.348), differentiation grade (p=0.972), disease 
relapse (p=0.408) and disease specific death (p=0.830), but it was significantly 
associated with lymph-node status (p<0.001, Table 3). Multivariate analysis showed 
that positive JMJD1A nuclear expression was an independent marker for lymph-node 
positivity, yielding an approximately 4-fold increased risk (OR=3.76, CI=1.21-11.74, 
Table 4). 
JMJD1A nuclear expression levels did not show a significant relation with tumor 
size (p=0.762), differentiation grade (p=0.888), lymph node status (p=0.992) and 
disease specific death (p=0.061), but it was significantly associated with disease relapse 
(p<0.040, Table 3). Multivariate analysis showed that high expression was an 
independent marker of disease relapse representing an increased risk over of 5 times, 
when compared to nuclear JMJD1A low expression (OR=5.09, CI=1.11-23.38, Table 
5). 
Disease free and disease specific survival did not show association with 
JMJD1A nuclear expression positivity (p=0.902 and p=0.959, respectively, data not 
show). JMJD1A nuclear expression levels did not show an association with disease free 
survival either (p=0.172, data not show), but it was significantly associated with disease 
specific survival (p=0.039). According to a 36 month after surgery follow up, 
approximately 60% of cases with high expression died of the disease, as compared to 
approximately 35% of death in patients with low nuclear expression (Figure 1). 
Multivariate analysis revealed that JMJD1A high nuclear expression is an independent 
marker for faster disease specific death, with a 2.5 fold increased risk when compared to 
low expression (HR=2.56, CI=1.21-5.41, Table 5). 
 
DISCUSSION AND CONCLUSIONS 
JMJD1A protein promotes demethylation of histones, especialy at lysin-9 of bi-
methylated histone H3 (H3K9me2) or mono-methylated (H3K9me1) [10]. Histone 
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demethylation alters chromatin structure resulting in gene expression changes, DNA 
repair, replication [11], as well as cell differentiation [12]. JMJD1A expression has been 
related to development and prognosis of diverse tumor types [13-16]. 
Our results suggest that positive JMJD1A nuclear expression increases lymph 
node metastasis risk by 4-fold, whereas cytoplasmic expression increases risk by over 
11-fold. Colorectal cancer studies have correlated high JMJD1A expression with an 
augmented risk for lymph node positivity by over 6-fold [13]. 
We also show that cytoplasmic JMJD1A expression is related with tumor size, 
which could be due to activation of cell cycle regulating genes, such as Cyclin 
A1(CCNA1) [23], adrenomedullin (ADM) [11] and Cyclin D1 (CCND1) [24]. 
JMJD1A gene expression results in activation of homeobox A1 (HOXA1) gene, 
which induces CCND1 gene expression, increasing cell cycling. Over activation of 
CCND1 may result in an uncontrolled proliferation state and tumor metastasis. IN 
colorectal cancer, under hypoxic conditions, JMJD1A expression has been related to 
ADM protein expression and tumor cell growth [11]. 
Hypoxic and starved tumor cells may show a more aggressive behavior, due to 
profound metabolic changes [15,25], which favors the hypothesis that large and hypoxic 
tumor cells may migrate to other regions in search of more favorable conditions 
(metastasis). Our results show that strong nuclear JMJD1A expression correlates with a 
5-fold increased risk of disease relapse. In addition, strong nuclear expression was 
related with worse disease specific survival. Similar results were described for 
hepatocellular carcinoma, in which strong expression was related with higher relapse 
risk [26]. 
Therefore, JMJD1A may be considered a marker of worse prognosis, for been 
related with epigenetic activation of various genes associated with tumor growth and 
treatment resistance [13,25,27]. 
Moreover, JMJD1A is related with non-differentiation of stem cells [12]. 
Indifferentiated cell are responsible for tumor initiation, progression and aggressiveness 
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[28]. In conclusion, the present study proposes JMJD1A as a promising prognostic 
marker for oral and oropharyngeal squamous cell carcinomas. 
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FIGURE LEGEND 
Figure 1. Survival plots. Disease specific survival according to JMJD1A nuclear 
expression. 
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TABLES 
Table 1. Epidemiological features. 
Features 
Total 
No. (%) 
Gender 
  
Female 12 (15.0) 
Male 68 (85.0) 
Age, yr 
  
median 54.4, df±10,4 
  
Smoker 57 (71.3) 
Alcohol user 44 (55.0) 
Tumor sites 
  
Oral cavity 60 (75.0) 
Oropharingeal 20 (25.0) 
Tumor stage 
  
I, II 19 (23.8) 
III 20 (25.0) 
IV 41 (51.3) 
Total 80 (100.0) 
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Table 2. JMJD1A expression in primary tumor cells, according to cell localization. 
JMJD1A expression 
Cellular localization 
Nuclear Cytoplasmic 
p 
No. (%) No. (%) 
      
Negative 27 (33.8) 11 (13.8) <0.001 
Low 31 (38.8) 63 (78.8) 
 
High 22 (27.5) 6 (7.5) 
 
Total 80 (100.0) 80 (100.0) 
 
 
182 
 
Table 3. Clinical and pathological tumor features and their association with JMJD1A expression, according to cell localization. 
Features 
JMJD1A expression 
Nuclear 
 
Cytoplasmic 
Negative Positive 
p  
Low High 
p  
Negative Positive 
p  
Low High 
p 
No. (%) No. (%) 
 
No. (%) No. (%) 
 
No. (%) No. (%) 
 
No. (%) No. (%) 
Tumor size (T) 
¥
 
                       
T1, T2 14 (51.9) 19 (35.8) 0.348 
 
12 (38.7) 7 (31.8) 0.762 
 
6 (54.5) 27 (39.1) 0.023 
 
24 (38.1) 3 (50.0) 0.432 
T3 6 (22.2) 13 (24.5) 
  
8 (25.8) 5 (22.7) 
  
5 (45.5) 14 (20.3) 
  
12 (19.0) 2 (33.3) 
 
T4 7 (25.9) 21 (39.6) 
  
11 (35.5) 10 (45.5) 
  
0 (0.0) 28 (40.6) 
  
27 (42.9) 1 (16.7) 
 
Lymph node (N) 
¥
 
                       
Negative 18 (66.7) 15 (28.3) <0.001 
 
9 (29.0) 6 (27.3) 0.888 
 
10 (90.9) 23 (33.3) <0.001 
 
22 (34.9) 1 (16.7) 0.341 
Positive 9 (33.3) 38 (71.7) 
  
22 (71.0) 16 (72.7) 
  
1 (9.1) 46 (66.7) 
  
41 (65.1) 5 (83.3) 
 
Differentiation 
                       
Well 11 (40.7) 22 (41.5) 0.972 
 
13 (41.9) 9 (40.9) 0.992 
 
6 (54.5) 27 (39.1) 0.619 
 
25 (39.7) 2 (33.3) 0.590 
Moderate 13 (48.1) 26 (49.1) 
  
15 (48.4) 11 (50.0) 
  
4 (36.4) 35 (50.7) 
  
31 (49.2) 4 (66.7) 
 
Poorly 3 (11.1) 5 (9.4) 
  
3 (9.7) 2 (9.1) 
  
1 (9.1) 7 (10.1) 
  
7 (11.1) 0 (0.0) 
 
Disease relapse 
                       
No 11 (40.7) 16 (30.2) 0.408 
 
13 (41.9) 3 (13.6) 0.040 
 
5 (45.5) 22 (31.9) 0.414 
 
22 (34.9) 0 (0.0) 0.081 
Yes 16 (59.3) 35 (66.0) 
  
18 (58.1) 17 (77.3) 
  
6 (54.5) 45 (65.2) 
  
39 (61.9) 6 (100.0) 
 
Not available
§
 0 (0.0) 2 (3.8) 
  
0 (0.0) 2 (9.1) 
  
0 (0.0) 2 (2.9) 
  
2 (3.2) 0 (0.0) 
 
Disease specific death 
                       
No 13 (48.1) 29 (54.7) 0.830 
 
14 (45.2) 15 (68.2) 0.061 
 
6 (54.5) 36 (52.2) 0.434 
 
31 (49.2) 5 (83.3) 0.178 
Yes 10 (37.0) 20 (37.7) 
  
15 (48.4) 5 (22.7) 
  
3 (27.3) 27 (39.1) 
  
26 (41.3) 1 (16.7) 
 
Not available
§
 4 (14.8) 4 (7.5) 
  
2 (6.5) 2 (9.1) 
  
2 (18.2) 6 (8.7) 
  
6 (9.5) 0 (0.0) 
 
Total 27 (33.8) 53 (66.3) 
  
31 (58.5) 22 (41.5) 
  
11 (13.8) 69 (86.3) 
  
63 (91.3) 6 (8.7) 
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¥
 TNM classification 3rd edition. 
§
 Not available (not considered in the statistical calculations). 
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Table 4. Multivariate analysis of the relationship between lymph node status and 
JMJD1A expression. 
Features 
Multivariate Analysis 
Lymph nodes (N)
 ¥
 
OR (CI 95%) p 
JMJD1A Nuclear expression 
  
Negative 1 
 
Positive 3.76 (1.21-11.74) 0.022 
JMJD1A Cytoplasmic expression 
  
Negative 1 
 
Positive 11.46 (1.10-119.38) 0.041 
Tumor size (T)
 ¥
 
  
T1, T2 1 
 
T3 2.93 (0.68-12.64) 0.151 
T4 3.77 (1.06-13.41) 0.041 
Differentiation 
  
Well 1 
 
Moderate 1.76 (0.56-5.59) 0.337 
Poorly 3.11 (0.34-28.06) 0.312 
¥
 TNM classification 3rd edition. 
 
 Table 5. Multivariate analysis of the relationship between JMJD1A expression and prognosis. 
Variable 
Multivariate Analysis  Cox Proportional 
Disease relapse 
 
Disease specific survival 
OR (CI 95%) P 
 
HR (CI 95%) p 
JMJD1A Nuclear expression 
     
Low 1 
  
1 
 
High 5.09 (1.11-23.38) 0.036 
 
2.56 (1.21-5.41) 0.014 
Stage tumor 
     
I, II 1 
  
1 
 
III 2.50 (0.35-17.91) 0.362 
 
3.24 (0.82-12.82) 0.094 
IV 3.37 (0.60-19.11) 0.170 
 
4.42 (1.27-15.44) 0.020 
 
